[
  {
    "path": "hema/06-17-2022/",
    "title": "Fri Jun 17 2022",
    "description": "78 articles - From Friday Jun 10 2022 to Friday Jun 17 2022",
    "author": [],
    "date": "2022-06-17",
    "categories": [],
    "contents": "\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nparm_toc.knith1 {font-size: 34px;}\r\n       h1.title {font-size: 38px;}\r\n       h2 {font-size: 30px;}\r\n       h3 {font-size: 24px;}\r\n       h4 {font-size: 18px;}\r\n       h5 {font-size: 16px;}\r\n       h6 {font-size: 12px;}\r\n       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}\r\n       pre:not([class]) { background-color: white }\r\n  code{white-space: pre-wrap;}\r\n  span.smallcaps{font-variant: small-caps;}\r\n  span.underline{text-decoration: underline;}\r\n  div.column{display: inline-block; vertical-align: top; width: 50%;}\r\n  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\r\n  ul.task-list{list-style: none;}\r\n    code{white-space: pre;}\r\nif (window.hljs) {\r\n  hljs.configure({languages: []});\r\n  hljs.initHighlightingOnLoad();\r\n  if (document.readyState && document.readyState === \"complete\") {\r\n    window.setTimeout(function() { hljs.initHighlighting(); }, 0);\r\n  }\r\n}\r\n\r\n.main-container {\r\n  max-width: 940px;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n}\r\nimg {\r\n  max-width:100%;\r\n}\r\n.tabbed-pane {\r\n  padding-top: 12px;\r\n}\r\n.html-widget {\r\n  margin-bottom: 20px;\r\n}\r\nbutton.code-folding-btn:focus {\r\n  outline: none;\r\n}\r\nsummary {\r\n  display: list-item;\r\n}\r\npre code {\r\n  padding: 0;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs {\r\n  display: inline-table;\r\n  max-height: 500px;\r\n  min-height: 44px;\r\n  overflow-y: auto;\r\n  border: 1px solid #ddd;\r\n  border-radius: 4px;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {\r\n  content: \"<U+E258>\";\r\n  border: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active {\r\n  display: block;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li > a,\r\n.tabset-dropdown > .nav-tabs > li > a:focus,\r\n.tabset-dropdown > .nav-tabs > li > a:hover {\r\n  border: none;\r\n  display: inline-block;\r\n  border-radius: 4px;\r\n  background-color: transparent;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li {\r\n  display: block;\r\n  float: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li {\r\n  display: none;\r\n}\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nGuidelines\r\nMeta-analysis\r\nOriginal articles\r\nReviews&Editorials\r\nLetters&Replies\r\nOthers\r\n\r\n\r\n\r\n$(function () {\r\n          $('#goTop').goTop({\"container\":\"\",\"appear\":200,\"scrolltime\":800,\"src\":\"fas fa-chevron-up\",\"width\":45,\"place\":\"left\",\"color\":\"\",\"fadein\":500,\"fadeout\":500,\"opacity\":0.5,\"marginX\":2,\"marginY\":2,\"zIndex\":9});\r\n         });\r\nGuidelines\r\nGuidelines, position statements, white papers, technical reviews, consensus statements, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#mxemitakbj .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#mxemitakbj .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mxemitakbj .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#mxemitakbj .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#mxemitakbj .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#mxemitakbj .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mxemitakbj .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#mxemitakbj .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#mxemitakbj .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#mxemitakbj .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#mxemitakbj .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#mxemitakbj .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#mxemitakbj .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#mxemitakbj .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#mxemitakbj .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#mxemitakbj .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#mxemitakbj .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#mxemitakbj .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#mxemitakbj .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#mxemitakbj .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#mxemitakbj .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#mxemitakbj .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#mxemitakbj .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#mxemitakbj .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mxemitakbj .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#mxemitakbj .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mxemitakbj .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#mxemitakbj .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#mxemitakbj .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#mxemitakbj .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#mxemitakbj .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#mxemitakbj .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#mxemitakbj .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#mxemitakbj .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#mxemitakbj .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Ann Oncol\r\n    Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upâ€ .\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCA Cancer J Clin\r\n    An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma.\r\nThe literature review, consensus statements, and algorithms presented in this report can serve as a framework guiding treatment decisions for patients. CA Cancer J Clin. 2022; 72:000-000.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMeta-analysis\r\nmeta-analyses and systematic reviews\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#wlkxxxqcam .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#wlkxxxqcam .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#wlkxxxqcam .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#wlkxxxqcam .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#wlkxxxqcam .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#wlkxxxqcam .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#wlkxxxqcam .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#wlkxxxqcam .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#wlkxxxqcam .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#wlkxxxqcam .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#wlkxxxqcam .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#wlkxxxqcam .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#wlkxxxqcam .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#wlkxxxqcam .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#wlkxxxqcam .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#wlkxxxqcam .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#wlkxxxqcam .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#wlkxxxqcam .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#wlkxxxqcam .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#wlkxxxqcam .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#wlkxxxqcam .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#wlkxxxqcam .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#wlkxxxqcam .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#wlkxxxqcam .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#wlkxxxqcam .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#wlkxxxqcam .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#wlkxxxqcam .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#wlkxxxqcam .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#wlkxxxqcam .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#wlkxxxqcam .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#wlkxxxqcam .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#wlkxxxqcam .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#wlkxxxqcam .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#wlkxxxqcam .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#wlkxxxqcam .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    \r\n\r\n\r\nOriginal articles\r\nRCT, clinical trials, retrospective studies, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#sxzyvrrshk .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#sxzyvrrshk .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#sxzyvrrshk .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#sxzyvrrshk .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#sxzyvrrshk .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#sxzyvrrshk .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#sxzyvrrshk .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#sxzyvrrshk .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#sxzyvrrshk .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#sxzyvrrshk .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#sxzyvrrshk .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#sxzyvrrshk .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#sxzyvrrshk .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#sxzyvrrshk .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#sxzyvrrshk .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#sxzyvrrshk .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#sxzyvrrshk .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#sxzyvrrshk .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#sxzyvrrshk .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#sxzyvrrshk .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#sxzyvrrshk .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#sxzyvrrshk .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#sxzyvrrshk .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#sxzyvrrshk .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#sxzyvrrshk .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#sxzyvrrshk .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#sxzyvrrshk .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#sxzyvrrshk .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#sxzyvrrshk .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#sxzyvrrshk .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#sxzyvrrshk .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#sxzyvrrshk .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#sxzyvrrshk .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#sxzyvrrshk .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#sxzyvrrshk .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.\r\nFLT3-ITD mutation was associated with inferior survival in intermediate-1 (p=0.004) and TP53 in intermediate-2 (p=0.06) and high (p=0.02) risk disease;  the latter was fully accounted for by the close association between TP53 mutation and complex/monosomal karyotype while the observations regarding FLT3-ITD were not affected by treatment with midostaurin. AHSCT had a favorable impact on survival, most apparent in intermediate-1 (p<0.001), intermediate-2 (p=0.03), and high (p=0.01) risk disease. The proposed 3-factor survival model offers a novel prototype that is amenable to further enhancement by molecular information and was validated in an external cohort of 1,032 intensively-treated AML patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHLA-haploidentical transplantation for relapsed/refractory AML: better LFS with BM than with PBSC in patients = 55 years of age.\r\nIn contrast, in patients =55years of age, the use of PBSC versus BM was associated with higher non-relapse mortality (NRM) (HR = 1.7, P = 0.01), lower LFS (HR = 1.37, P = 0.026) and lower overall survival (OS) (HR = 1.33, P = 0.044). In conclusions, our data suggest that in patients =55years of age with active AML at HLA-haploidentical transplantation, the use of BM instead of PBSC as stem cell source results in lower NRM and better LFS. In contrast among younger patients, the use of PBSC results in at least a comparable LFS.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnn Oncol\r\n    Bendamustine is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas.\r\nBendamustine for lymphodepletion before tisagenlecleucel has efficacy similar to fludarabine/cyclophosphamide with reduced toxicities, including CRS, neurotoxicity. infectious and hematological toxicities, as well as reduced hospital utilization.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: Updated Analysis from the Phase 2 KEYNOTE-158 Study.\r\n Pembrolizumab demonstrated clinically meaningful and durable benefit, with high ORR of 30.8%, long median duration of response of 47.5 months, and manageable safety across a range of heavily pretreated, advanced MSI-H/dMMR noncolorectal cancers, providing support for use of pembrolizumab in this setting.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase 3 trial.\r\n Pimitespib significantly improved PFS and crossover-adjusted OS compared with placebo and had an acceptable safety profile in patients with advanced GIST refractory to standard TKIs.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nWhole genome and transcriptome analysis enhances precision cancer treatment options.\r\nIntegrating RNA expression and genome data illuminated treatment options that resulted in 46% of treated patients experiencing positive clinical benefit, supporting the use of comprehensive WGTA profiling in clinical cancer care. Clinical trial number NCT02155621.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia. \r\nExpression of this EVI1 splice variant enhanced the self-renewal of hematopoietic stem cells and introduction of mutant SF3B1 in mice bearing the humanized inv(3)(q21q26) allele resulted in generation of this novel EVI1 isoform in mice and hastened leukemogenesis in vivo. The mutant SF3B1 spliceosome depends upon an exonic splicing enhancer within EVI1 exon 13 to promote usage of a cryptic branch point and aberrant 3' splice site within intron 12 resulting in the generation of this isoform. These data provide a mechanistic basis for the frequent co-occurrence of SF3B1 mutations as well as new insights into the pathogenesis of myeloid leukemias harboring inv(3)/t(3; 3).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nComparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.\r\nThe ORR and CR rate were 49.9% and 29.9% in SCHOLAR-5 compared to 94.2% and 79.1% in ZUMA-5, for odds ratios of 16.2 (95%CI: 5.6-46.9) and 8.9 (95%CI: 4.3-18.3). Compared to available therapies, axi-cel demonstrated an improvement in meaningful clinical endpoints. This study suggests axi-cel may address an important unmet need for r/r FL patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCost Effectiveness of Polatuzumab Vedotin Combined with Chemoimmunotherapy in Untreated Diffuse Large B-cell Lymphoma.\r\nHowever, its cost-effectiveness is highly dependent on its long-term outcomes and CAR-T cost. Routine usage of pola-R-CHP would add significantly to healthcare expenditures. Price reductions or identification of subgroups that have maximal benefit would improve cost-effectiveness.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDeregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.\r\nAs we found loss of BAX in Richter's syndrome patients after venetoclax failure, we defined BAX-mediated apoptosis to be critical for drug resistance but not for disease progression of CLL into aggressive DLBCL in vivo. A compound screen revealed TRAIL-mediated apoptosis as a target to overcome BAX deficiency. Furthermore, antibody or CAR T cells eliminated venetoclax resistant lymphoma cells, paving a clinically applicable way to overcome venetoclax resistance.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nKIR3DL2 contributes to the typing of acute-type adult T-cell leukemia and is a potential therapeutic target.\r\nTo conclude, KIR3DL2 expression is associated with acute-type ATL. Transcription of KIR3DL2 might be triggered by HTLV-1 infection and is correlated with hypomethylation of the promoter. The benefit of targeting KIR3DL2 with lacutamab is being further explored in a randomized phase 2 study in peripheral T-cell lymphoma, including ATL (NCT04984837).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nQuercetin Ameliorates XIAP Deficiency Associated Hyperinflammation.\r\nIn experiments using human cells, quercetin greatly reduced IL-1ÃŸ secretion by monocytes following TNF-a stimulation (p<0.05). Our data suggest that quercetin may be an effective natural therapeutic for the prevention of XIAP deficiency-associated hyperinflammation. Clinical trials, including careful pharmacokinetic and pharmacodynamic studies to ensure that effective levels of quercetin can be obtained, are warranted.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSingle-cell multiomics reveal the scale of multi-layered adaptations enabling CLL relapse during venetoclax therapy.\r\nBoth the switch to alternative pro-survival factors and NF-kB activation largely dissipate following venetoclax discontinuation. Our studies reveal the extent of plasticity of CLL cells in their ability to evade venetoclax-induced apoptosis. Importantly, these findings pinpoint new approaches to circumvent venetoclax resistance and provide a specific biological justification for the strategy of venetoclax discontinuation once maximal response is achieved rather than maintaining long-term selective pressure with the drug.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSutimlimab in patients with cold agglutinin disease: Results of the randomized placebo-controlled phase 3 CADENZA trial.\r\nThese data demonstrate that sutimlimab has potential to be an important advancement in the treatment of CAD. (ClinicalTrials. gov: NCT03347422).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia.\r\nIn contrast, argatroban showed no effect on procoagulant platelets and aggregation but significantly inhibited VITT-mediated thrombus formation. Taken together, our data indicate that negatively charged anticoagulants can disrupt VITT-Ab/PF4 interactions, which might serve as an approach to reduce Ab-mediated complications in VITT. Our results should be confirmed, however, in a clinical setting before a recommendation regarding the selection of anticoagulants in VITT patients could be made.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nUnique characteristics of lung resident neutrophils are maintained by PGE2/PKA/Tgm2-mediated signaling.\r\nNeutrophils from Tgm2-/- mice release high levels of inflammatory cytokines in response to LPS. Lung damage is significantly exacerbated in Tgm2-/- mice in an LPS-induced acute respiratory distress syndrome model. Collectively, we demonstrate that prostaglandin E2 is a key factor for the generation of LNs with unique immune suppressive characteristics, acting through protein kinase A and Tgm2, and LNs play essential roles in the protection of the lungs against pathogenic inflammation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    CIC-39Na reverses the thrombocytopenia that characterizes tubular aggregate myopathy.\r\nI115F mice was in platelet clearance and in the levels of platelet cytosolic basal Ca2+. Both were restored upon treatment of animals with CIC-39Na. This finding paves the way to a pharmacological treatment strategy for thrombocytopenia in tubular aggregate myopathy patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDeveloping and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study.\r\nBoth calibration plots illustrated a high degree of consistency in the estimated and observed risk. In addition, the decision curve analysis showed a considerable net benefit for patients. Thus, an application (47.94.162.105:8080/ich/) was established for users to predict 30-day mortality when ICH occurred in adult patients with ITP.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEnhanced systemic antilymphoma immune response by photothermal therapy with CpG deoxynucleotide coated nanoparticles.\r\nWe found that the CpG/PTT groups had significant reduction in growth in both treated (primary) and untreated (secondary) tumors suggesting an improved abscopal response, with a concomitant increase in CD8/CD4 ratio and cytotoxic T cell/regulatory T cell ratio in both the primary and secondary tumor compared with CpG/RT. Dendritic cells in the primary and secondary draining lymph nodes had increased maturation markers in the CpG/PTT group, and the effector memory T cells (both CD4 and CD8) in the secondary tumor and the spleen were increased, suggesting a systemic vaccination effect. These data suggest that in a lymphoma model, PTT using a CpG nanoparticle platform resulted in enhanced in situ vaccination and abscopal response compared with RT.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenetic characterization and drug sensitivity study of newly derived HGBL double/triple-hit lymphoma cell lines.\r\nSilvestrol and Dinaciclib generally showed outstanding activities and the newly derived cell lines tended to be most responsive. The BL cell line Jijoye showed a completely different pattern of response. A panel of well characterized D/TH lymphoma lines would be very helpful in preclinical studies of targeted agents.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenomic characterization of lymphomas in patients with inborn errors of immunity.\r\nThe latter, BRWD3, is furthermore preferentially mutated in tumors of a subgroup of activated phosphoinositide 3-kinase delta (PI3Kd) syndrome patients. We also identified five genomic mutational signatures, including two DNA repair deficiency-related signatures, in IEI-associated lymphomas and a strikingly high number of inter- and intrachromosomal structural variants in the tumor genome of a Bloom syndrome patient. In summary, our comprehensive genomic characterization of lymphomas derived from patients with rare genetic disorders expands our understanding of lymphomagenesis and provides new insights for targeted therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHematopoietic stem cell boost for persistent neutropenia after CAR-T cell therapy: a GLA/DRST study.\r\nHematotoxicity after chimeric antigen receptor (CAR)-T cell therapy is associated with infection and death but management remains unclear. We report results of 31 patients receiving hematopoietic stem cell boost (HSCB;  30 autologous, 1 allogeneic) for either sustained severe neutropenia of grade 4 ( 38 days prior to HSCB (44%;  p=0.029). In conclusion, early or prophylactic HSCB showed quick response and improved outcomes for sustained moderate to severe neutropenia after CAR-T.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIn vivo HSC transduction in rhesus macaques with an HDAd5/3+ vector targeting desmoglein 2 and transiently over-expressing cxcr4.\r\nIn vivo transduction with a HDAd5/3+GFP/cxcr4 vector at a low dose of 0.4x1012vp/kg resulted in up to 7% of GFP-positive CD34+/CD45RA-/CD90+ cells in the bone marrow. This transduction rate is a solid basis for in vivo base or prime editing in combination with natural or drug-induced expansion of edited HSCs. Furthermore, our study provides new insights into HSC biology and trafficking after mobilization in non-human primates.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLongitudinal Study of Glomerular Hyperfiltration in Adults with Sickle Cell Anemia: A Multicenter Pooled Analysis.\r\nUsing CKD-EPI-2009, this decline was associated with male sex (HR: 2.20, 95%CI: 1.26, 3.87;  p=0.006), systolic blood pressure (SBP) (HR: 1.02, 95%CI: 1.01, 1.04;  p=0.01) and hydroxyurea use (HR: 1.74, 95%CI: 1.002, 3.03;  p=0.05). Using CKD-EPI-2021, decline of eGFR to normal was only associated with male sex (HR: 3.39, 95% CI: 2.01, 5.69;  p<0.0001). Decline to normal eGFR range from hyperfiltration occurs earlier in males, those on hydroxyurea and with higher SBP.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNon-canonical Sonic Hedgehog signaling amplifies platelet reactivity and thrombogenicity.\r\nRemarkably, agonist-induced thrombogenic responses in platelets, which include platelet aggregation, granule secretion and spreading on immobilized fibrinogen, were significantly attenuated by inhibition of Hedgehog signaling, thus implicating inputs from Shh in potentiation of agonist-mediated platelet activation. In consistence, inhibition of Shh pathway significantly impaired arterial thrombosis in mice. Taken together, above observations strongly support a feed-forward loop of platelet stimulation triggered locally by Shh, similar to ADP and thromboxane A2, that contributes significantly to stability of occlusive arterial thrombus and that can be investigated as potential therapeutic target in thrombotic disorders.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNurse-like cells sequester B cells in chronic lymphocytic leukemia disorganized lymph nodes via an alternative production of CCL21.\r\nOur results indicate NLCs as providers of an alternative source of CCL21, taking over the physiological task of follicular reticular cells (FRCs) whose network is deeply altered in CLL lymph nodes. Moreover, CCL21, by retaining malignant B cells, provide a protective environment for their niching and survival thus allowing immune tumor survey evasion and resistance to treatment. These findings argue for a specific targeting or re-education of NLCs as a new immunotherapy strategy for this still deadly disease.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOutcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum. \r\nIn this context, we observed that harboring more than 3 mutated genes, ASXL1 mutations and a peripheral blood monocyte percentage above 20% significantly predicted shorter time of progression of OM-CMML into overt CMML. These variables were also detected as independent adverse prognostic factors for OS in OM-CMML. These data support the consideration of OM-CMML as the first evolutionary stage within the proliferative continuum of CMML.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPredicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism.\r\nIncidence of major bleeding events per 100 person-years in high- and non-high-risk patients, respectively, were 3.9 (95% confidence interval, 3.0-5.1) and 1.1 (0.8-1.4) using the newly derived CHAP model (creatinine, hemoglobin, age, and use of antiplatelet agent), 3.3 (2.6-4.1) and 1.0 (0.7-1.3) using modified ACCP, 5.3 (0.6-19.2) and 1.7 (1.4-2.0) using modified RIETE, 3.1 (2.3-3.9) and 1.1 (0.9-1.5) using modified VTE-BLEED, 5.2 (3.3-7.8) and 1.5 (1.2-1.8) using modified HAS-BLED, and 4.8 (1.3-12.4) and 1.7 (1.4-2.0) using modified OBRI scores. Modified versions of the ACCP, VTE-BLEED, and HAS-BLED scores help identify patients with unprovoked VTE who are at high risk of major bleeding and should be considered for discontinuation of anticoagulation after 3-6 months of initial treatment. The CHAP model may further improve estimation of bleeding risk by using continuous predictor variables, but external validation is required before its implementation in clinical practice.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRisk of diabetes and the impact on preexisting diabetes in lymphoma patients treated with steroid-containing immunochemotherapy.\r\nIn a landmark analysis at one year, DM patients with lymphoma had decreased risks of insulin dependency compared to comparators. Time-varying IRRs showed a higher CVD risk for NHL patients with DM as compared to comparators in the first year after treatment. NHL patients treated with steroid-containing immunochemotherapy regimens have a clinically insignificant increased risk of DM in the first year following treatment, and patients with pre-existing DM have a temporary increased risk of insulin prescriptions and CVD.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.\r\nAn Andersen-Gill regression model on OS revealed ELN favorable-risk (HR, 0.34;  P=0.006) and trisomy 4 as sole abnormality (HR, 0.41 P=0.01) as favorable factors, whereas age with a difference of ten years (HR, 1.15, P=0.11), female gender (OR, 0.74;  P=0.20) and allo-HCT (OR, 0.64;  P=0.14) had no significant impact. In our cohort, patients with trisomy 4 as a sole abnormality had a high CR rate and favorable clinical outcome. Allo-HCT seems not to improve OS.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDaratumumab for treatment-refractory acquired idiopathic pure red cell aplasia.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImmune thrombocytopenia (ITP): diagnosis including secondary ITP, and selection of second line treatment\r\nDuring review of potential second-line treatment options, we also briefly touch upon novel treatments. Finally, there is a short section on refractory disease drawn from our extensive review in Blood in February 2020(1). The clinical nature of the discussions replete with figures and tables and with interspersion of pearls regarding efficacy and toxicity at different ages and genders, will serve the reader in management of \"typical\" adult patients who develop persistent and chronic ITP.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMonomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.\r\nThe median overall survival (OS) of 63 patients (43/63 only received chemotherapy after initial surgery) was 7.8 months. Multivariate analysis found a strong negative impact on outcome of MYC expression, TP53 mutation, STAT5B mutation and poor performance status while aberrant B-cell marker expression (20% of cases) correlated with better survival. In conclusion, MEITL is an aggressive disease with resistance to conventional therapy, predominantly characterized by driver gene alterations deregulating histone methylation and JAK/STAT signalling and encompasses genetic and morphologic variants associated with very high clinical risk.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPET-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T-cells.\r\nResponse at M3 evaluated in 90 (57%) patients was prognostic for PFS with lower discrimination (HR=3.28 (95%CI: 1.5-7.0), p=0.003) but did not predict OS (HR = 0.61 (95%CI: 0.2-2.3) p=0.45). Patients with high baseline total metabolic tumor volume (TMTV) >80ml had worse PFS (HR=2.05 (95%CI: 1.2-3.5), p=0.009) and OS (HR=4.52 (95%CI: 2.5-8.1), p80ml, and DS-5 at M1 for OS. In conclusion, baseline TMTV and response at M1 strongly predicts outcomes of patients with R/R LBCL undergoing CAR T-cells.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPrediction of complete remission and survival in acute myeloid leukemia using supervised machine learning.\r\nFor prediction of CR and 2-year OS, AUROCs ranged between 0.77 - 0.86 and 0.63 and 0.74, respectively in our test set and 0.71 - 0.80 and 0.65 - 0.75 in the external validation cohort. We demonstrate the feasibility of ML for risk stratification in AML as a model disease for hematologic neoplasms using a scalable and reusable ML framework. Our study illustrates the clinical applicability of ML as a decision support system in hematology.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.\r\nThe type II MET-TKI foretinib may be an appropriate second-line treatment for NSCLCs carrying METex14 after campatinib/tepotinib treatment failure by secondary mutations at residue D1228 or Y1230.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nLancet Haematol\r\n    Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial.\r\nOur study supports short treatment if patients are afebrile after 3 days of carbapenem treatment. However, because secondary analyses suggested that serious adverse events and all-cause mortality occurred more often in patients who are presistantly febrile the short treatment group, we recommend vigilance for non-susceptible pathogens and early resumption of empirical therapy in patients who are deteriorating. Funding The Netherlands Organisation for Health Research and Development and Fonds NutsOhra.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.\r\nHowever, the CalDDR-GEx10 score was not associated with clinical outcome in patients treated with standard chemotherapy alone (ADE, N=242), implying the specificity of the CalDDR-GEx10 score to calicheamicin-induced DNA damage response. In multivariable models adjusted for risk group, FLT3-status, white blood cell count, and age, the CalDDR-GEx10 score remained a significant predictor of outcome in patients treated with ADE+GO. Our findings present a potential tool that can specifically assess response to calicheamicin-induced DNA damage preemptively via assessing diagnostic leukemic cell gene expression and guide clinical decisions related to treatment using GO.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL.\r\nInvestigation of metabolism in vitro and in vivo supported these findings, revealing reduced aerobic glycolysis and increased basal respiration in CD147 knockdown. In conclusion, our findings indicate that CD147 is of vital importance for ALK+ ALCL to maintain the high energy demand of rapid cell proliferation, promoting lactate export, and tumor growth. Furthermore, CD147 has the potential to serve as a novel therapeutic target in ALK+ ALCL, and warrants further investigation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.\r\nSignificant transcriptional alterations were identified in double-lesion mice, which were associated with activation of proinflammatory signals and repression of signals maintaining genome stability. Finally, KDM6B inhibitor reduced BM repopulating activity of double-lesion mice and tumor burden in mice transplanted with BM-HSPCs from CMML patients with TET2 mutations. These data indicate that TET2 deficiency and KDM6B overexpression cooperate in CMML pathogenesis of and that KDM6B could serve as a potential therapeutic target in this disease.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma.\r\nThe genetic profiles of ENTKCLs from Asian and Hispanic ethnic groups showed striking similarity, indicating shared pathogenetic mechanism and tumor evolution. Interestingly, we discovered a novel functional cooperation between activating STAT3 mutations and loss of the TSG, PRDM1, in promoting NK-cell growth and survival. This study provides a genetic roadmap for further analysis and facilitates investigation of actionable therapeutic opportunities in this aggressive lymphoma.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImpact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.\r\nThis subtle difference led to measurable transcript-type dependent variation in estimates of residual disease which could be corrected by (i) taking the qPCR amplification efficiency into account, (ii) using alternative RT-qPCR approaches or (iii) droplet digital PCR (ddPCR), a technique which is relatively insensitive to differences in amplification kinetics. In CML patients, higher levels of BCR::ABL1/GUSB were identified at diagnosis for patients expressing e13a2 (n=67) compared to e14a2 (n=78) when analysed by RT-qPCR (P=0.0005) but not ddPCR (P=0.5). These data indicate that widely used RT-qPCR assays result in subtly different estimates of disease depending on BCR::ABL1 transcript type;  these differences are small but may need to be considered for optimal patient management.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Adverse Events and All-Cause Mortality in Danish Patients with Cerebral Venous Thrombosis: A Nationwide Cohort Study.\r\n  Intracranial bleeding, ischemic stroke, and mortality risks were higher for patients with CVT than matched patients with VTE and the general population, particularly within 6 months after diagnosis.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nComparison of risk of serious cardiovascular events after haemorrhagic versus ischaemic stroke: a population-based study.\r\nThe risk of subsequent cardiovascular events is similar between patients with incident haemorrhagic or ischaemic stroke. Patients with previous haemorrhagic stroke should be regarded as a population at very-high risk of subsequent CVD.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImmunity in Stroke: The Next Frontier.\r\nOn one side, stroke induces a local neuroinflammatory response, in which the inflammatory activation of glial, endothelial and brain-invading cells contributes to lesion progression after stroke. On the other side, ischemic brain injury perturbs systemic immune homeostasis and results in long-lasting changes of systemic immunity. Here, we briefly summarize current concepts in local neuroinflammation and the systemic immune responses after stroke, and highlight two promising therapeutic strategies for poststroke inflammation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIs there Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Real-World Paired Serum and Plasma Testing.\r\nNo Abstract.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings.\r\n  In patients with AF, stable CAD, and preserved renal function, rivaroxaban underdose was associated with similar rates of thrombotic events but a lower incidence of hemorrhagic events than the standard dose. Clinical trial registration\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nReviews&Editorials\r\nPlenty of the editorials are available as full text through the publisher website using the provided link\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#ezfekjjjun .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#ezfekjjjun .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ezfekjjjun .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#ezfekjjjun .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#ezfekjjjun .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#ezfekjjjun .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ezfekjjjun .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#ezfekjjjun .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#ezfekjjjun .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#ezfekjjjun .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#ezfekjjjun .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#ezfekjjjun .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#ezfekjjjun .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#ezfekjjjun .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#ezfekjjjun .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#ezfekjjjun .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#ezfekjjjun .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#ezfekjjjun .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#ezfekjjjun .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#ezfekjjjun .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#ezfekjjjun .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#ezfekjjjun .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#ezfekjjjun .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#ezfekjjjun .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ezfekjjjun .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#ezfekjjjun .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ezfekjjjun .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#ezfekjjjun .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#ezfekjjjun .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#ezfekjjjun .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#ezfekjjjun .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#ezfekjjjun .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#ezfekjjjun .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#ezfekjjjun .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#ezfekjjjun .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Bispecific T-cell engagers for treatment of multiple myeloma.\r\nTCEs are also in development targeting the G protein-coupled receptor, class C group 5 member D (GPRC5D) and the Fc receptor homologue 5 (FcRH5). Main toxicities are cytokine release syndrome and cytopenias. Here we review the current development and future directions of TCEs in MM.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Defending the island against excess heme.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nExtramedullary hematopoietic stem cells.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHelping GATA1 make complex decisions.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHeparin or nonheparin anticoagulants for VITT.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nHLH treatment: smarter, not harder.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHyperuricemia reduces neutrophil function.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLinking epigenome regulation with DNA repair.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nShining a light on thrombin activation.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTransplant in older adults with AML: genomic wheat and chaff.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nWhy B(-)other? About the gap of unknowns in ALL.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Resistance to targeted therapies: delving into FLT3 and IDH.\r\nRecent advances in FLT3 and IDH targeted inhibition have improved response rates and overall survival in patients with mutations affecting these respective proteins. Despite this success, resistance mechanisms have arisen including mutations that disrupt inhibitor-target interaction, mutations impacting alternate pathways, and changes in the microenvironment. Here we review the role of these proteins in leukemogenesis, their respective inhibitors, mechanisms of resistance, and briefly ongoing studies aimed at overcoming resistance.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nCA Cancer J Clin\r\n    Examining the interrelationships between mindfulness-based interventions, depression, inflammation, and cancer survival.\r\nTherefore, it is conceivable that mindfulness programs can affect survival in this population. There are limited data on the long-term effects of mindfulness on depression and inflammatory markers in patients with cancer, and there are potential barriers to the implementation of mindfulness-based interventions as part of a comprehensive treatment plan. Therefore, it is necessary to further explore these questions through longitudinal studies to establish a survival correlation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.\r\nWe will also outline existing immunotherapeutic strategies, with a special focus on immune checkpoint inhibitors, chimeric antigen receptor therapy, and dendritic cell vaccines. Finally, we will summarize key discoveries in the field and discuss currently active clinical trials, including combination strategies, burgeoning technology like nucleic acid and nanoparticle therapy, and novel anticancer vaccines. This review aims to provide the most updated summary of the field of immunotherapy for GBM and offer both historical perspective and future directions to help inform clinical practice.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nLeukemia\r\n    Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research.\r\nIn this review, we present a comprehensive overview of technologies used for ctDNA detection and genotyping in B-cell lymphoma, focusing on pre-analytical and technical requirements, the advantages and limitations of various approaches, and highlight recent advances around improving sensitivity and suppressing technical errors. We broadly review potential applications of ctDNA in clinical practice and for translational research by describing how ctDNA might enhance lymphoma subtype classification, treatment response assessment, outcome prediction, and monitoring of measurable residual disease. We finally discuss how ctDNA could be implemented in prospective clinical trials as a novel surrogate endpoint and be utilized as a decision-making tool to guide lymphoma treatment in the future.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nLetters&Replies\r\nLetters to the editors and authorsâ€™ replies\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#bnzqqgasgf .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#bnzqqgasgf .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bnzqqgasgf .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#bnzqqgasgf .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#bnzqqgasgf .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#bnzqqgasgf .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bnzqqgasgf .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#bnzqqgasgf .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#bnzqqgasgf .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#bnzqqgasgf .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#bnzqqgasgf .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#bnzqqgasgf .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#bnzqqgasgf .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#bnzqqgasgf .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#bnzqqgasgf .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#bnzqqgasgf .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#bnzqqgasgf .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#bnzqqgasgf .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#bnzqqgasgf .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#bnzqqgasgf .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#bnzqqgasgf .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#bnzqqgasgf .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#bnzqqgasgf .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#bnzqqgasgf .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bnzqqgasgf .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#bnzqqgasgf .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bnzqqgasgf .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#bnzqqgasgf .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#bnzqqgasgf .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#bnzqqgasgf .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#bnzqqgasgf .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#bnzqqgasgf .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#bnzqqgasgf .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#bnzqqgasgf .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#bnzqqgasgf .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Immunogenicity and Clinical Efficacy of Anti-Sars-Cov-2 Vaccination in Patients with Hematological Malignancies: Results of A Prospective Cohort Study of 365 Patients.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMulti-organ Dysfunction Secondary to Abrupt Discontinuation of Voxelotor in a Patient with Severe Sickle Cell Disease.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOutcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTACI variants as underlying condition in autoimmune neutropenia: description of four cases.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nOthers\r\nall remaining publications eg case reports, images of the month, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#fmanafvfad .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#fmanafvfad .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fmanafvfad .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#fmanafvfad .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#fmanafvfad .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#fmanafvfad .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fmanafvfad .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#fmanafvfad .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#fmanafvfad .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#fmanafvfad .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#fmanafvfad .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#fmanafvfad .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#fmanafvfad .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#fmanafvfad .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#fmanafvfad .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#fmanafvfad .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#fmanafvfad .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#fmanafvfad .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#fmanafvfad .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#fmanafvfad .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#fmanafvfad .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#fmanafvfad .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#fmanafvfad .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#fmanafvfad .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fmanafvfad .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#fmanafvfad .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fmanafvfad .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#fmanafvfad .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#fmanafvfad .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#fmanafvfad .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#fmanafvfad .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#fmanafvfad .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#fmanafvfad .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#fmanafvfad .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#fmanafvfad .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood\r\n    Extranodal natural killer/T-cell lymphoma of the palate.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFlorid reactive follicular hyperplasia with exuberant HHV8 infection.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenetics and outcome in older AML transplant.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRural-urban disparities in place of death in hematologic malignancies in the U.S. 2003-2019.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    Unbiased decision-making for acute myeloid leukemia still needed.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    Climate change and haematology: perspectives from the Philippines.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCounting the carbon cost of heparin: an evolving tragedy of the commons?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe long and short of antibiotic management for neutropenic fever in patients with haematological malignancy.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Remodeling of the m6A RNA landscape in the conversion of acute lymphoblastic leukemia cells to macrophages.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n// add bootstrap table styles to pandoc tables\r\nfunction bootstrapStylePandocTables() {\r\n  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');\r\n}\r\n$(document).ready(function () {\r\n  bootstrapStylePandocTables();\r\n});\r\n\r\n\r\n\r\n$(document).ready(function () {\r\n  window.buildTabsets(\"TOC\");\r\n});\r\n\r\n$(document).ready(function () {\r\n  $('.tabset-dropdown > .nav-tabs > li').click(function () {\r\n    $(this).parent().toggleClass('nav-tabs-open');\r\n  });\r\n});\r\n\r\n  (function () {\r\n    var script = document.createElement(\"script\");\r\n    script.type = \"text/javascript\";\r\n    script.src  = \"https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML\";\r\n    document.getElementsByTagName(\"head\")[0].appendChild(script);\r\n  })();\r\n\r\n\r\n\r\n\r\n\r\n",
    "preview": {},
    "last_modified": "2022-06-18T06:46:58-04:00",
    "input_file": {}
  },
  {
    "path": "hema/06-10-2022/",
    "title": "Fri Jun 10 2022",
    "description": "78 articles - From Friday Jun 03 2022 to Friday Jun 10 2022",
    "author": [],
    "date": "2022-06-10",
    "categories": [],
    "contents": "\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nparm_toc.knith1 {font-size: 34px;}\r\n       h1.title {font-size: 38px;}\r\n       h2 {font-size: 30px;}\r\n       h3 {font-size: 24px;}\r\n       h4 {font-size: 18px;}\r\n       h5 {font-size: 16px;}\r\n       h6 {font-size: 12px;}\r\n       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}\r\n       pre:not([class]) { background-color: white }\r\n  code{white-space: pre-wrap;}\r\n  span.smallcaps{font-variant: small-caps;}\r\n  span.underline{text-decoration: underline;}\r\n  div.column{display: inline-block; vertical-align: top; width: 50%;}\r\n  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\r\n  ul.task-list{list-style: none;}\r\n    code{white-space: pre;}\r\nif (window.hljs) {\r\n  hljs.configure({languages: []});\r\n  hljs.initHighlightingOnLoad();\r\n  if (document.readyState && document.readyState === \"complete\") {\r\n    window.setTimeout(function() { hljs.initHighlighting(); }, 0);\r\n  }\r\n}\r\n\r\n.main-container {\r\n  max-width: 940px;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n}\r\nimg {\r\n  max-width:100%;\r\n}\r\n.tabbed-pane {\r\n  padding-top: 12px;\r\n}\r\n.html-widget {\r\n  margin-bottom: 20px;\r\n}\r\nbutton.code-folding-btn:focus {\r\n  outline: none;\r\n}\r\nsummary {\r\n  display: list-item;\r\n}\r\npre code {\r\n  padding: 0;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs {\r\n  display: inline-table;\r\n  max-height: 500px;\r\n  min-height: 44px;\r\n  overflow-y: auto;\r\n  border: 1px solid #ddd;\r\n  border-radius: 4px;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {\r\n  content: \"<U+E258>\";\r\n  border: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active {\r\n  display: block;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li > a,\r\n.tabset-dropdown > .nav-tabs > li > a:focus,\r\n.tabset-dropdown > .nav-tabs > li > a:hover {\r\n  border: none;\r\n  display: inline-block;\r\n  border-radius: 4px;\r\n  background-color: transparent;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li {\r\n  display: block;\r\n  float: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li {\r\n  display: none;\r\n}\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nGuidelines\r\nMeta-analysis\r\nOriginal articles\r\nReviews&Editorials\r\nLetters&Replies\r\nOthers\r\n\r\n\r\n\r\n$(function () {\r\n          $('#goTop').goTop({\"container\":\"\",\"appear\":200,\"scrolltime\":800,\"src\":\"fas fa-chevron-up\",\"width\":45,\"place\":\"left\",\"color\":\"\",\"fadein\":500,\"fadeout\":500,\"opacity\":0.5,\"marginX\":2,\"marginY\":2,\"zIndex\":9});\r\n         });\r\nGuidelines\r\nGuidelines, position statements, white papers, technical reviews, consensus statements, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#njhhjcqixg .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#njhhjcqixg .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#njhhjcqixg .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#njhhjcqixg .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#njhhjcqixg .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#njhhjcqixg .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#njhhjcqixg .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#njhhjcqixg .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#njhhjcqixg .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#njhhjcqixg .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#njhhjcqixg .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#njhhjcqixg .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#njhhjcqixg .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#njhhjcqixg .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#njhhjcqixg .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#njhhjcqixg .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#njhhjcqixg .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#njhhjcqixg .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#njhhjcqixg .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#njhhjcqixg .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#njhhjcqixg .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#njhhjcqixg .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#njhhjcqixg .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#njhhjcqixg .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#njhhjcqixg .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#njhhjcqixg .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#njhhjcqixg .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#njhhjcqixg .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#njhhjcqixg .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#njhhjcqixg .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#njhhjcqixg .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#njhhjcqixg .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#njhhjcqixg .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#njhhjcqixg .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#njhhjcqixg .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood\r\n    The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee.\r\nMajor findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification (ICC) of mature lymphoid, histiocytic, and dendritic cell tumors.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMeta-analysis\r\nmeta-analyses and systematic reviews\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#bhrmftycdh .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#bhrmftycdh .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bhrmftycdh .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#bhrmftycdh .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#bhrmftycdh .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#bhrmftycdh .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bhrmftycdh .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#bhrmftycdh .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#bhrmftycdh .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#bhrmftycdh .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#bhrmftycdh .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#bhrmftycdh .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#bhrmftycdh .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#bhrmftycdh .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#bhrmftycdh .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#bhrmftycdh .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#bhrmftycdh .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#bhrmftycdh .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#bhrmftycdh .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#bhrmftycdh .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#bhrmftycdh .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#bhrmftycdh .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#bhrmftycdh .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#bhrmftycdh .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bhrmftycdh .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#bhrmftycdh .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bhrmftycdh .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#bhrmftycdh .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#bhrmftycdh .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#bhrmftycdh .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#bhrmftycdh .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#bhrmftycdh .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#bhrmftycdh .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#bhrmftycdh .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#bhrmftycdh .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    \r\n\r\n\r\nOriginal articles\r\nRCT, clinical trials, retrospective studies, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#bkszrzxjrj .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#bkszrzxjrj .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bkszrzxjrj .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#bkszrzxjrj .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#bkszrzxjrj .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#bkszrzxjrj .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bkszrzxjrj .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#bkszrzxjrj .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#bkszrzxjrj .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#bkszrzxjrj .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#bkszrzxjrj .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#bkszrzxjrj .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#bkszrzxjrj .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#bkszrzxjrj .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#bkszrzxjrj .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#bkszrzxjrj .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#bkszrzxjrj .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#bkszrzxjrj .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#bkszrzxjrj .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#bkszrzxjrj .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#bkszrzxjrj .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#bkszrzxjrj .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#bkszrzxjrj .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#bkszrzxjrj .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bkszrzxjrj .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#bkszrzxjrj .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bkszrzxjrj .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#bkszrzxjrj .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#bkszrzxjrj .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#bkszrzxjrj .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#bkszrzxjrj .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#bkszrzxjrj .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#bkszrzxjrj .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#bkszrzxjrj .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#bkszrzxjrj .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Ann Oncol\r\n    Impact of acetaminophen on the efficacy of immunotherapy in cancer patients.\r\n This study provides strong pre-clinical and clinical evidence of the role of APAP as a potential suppressor of antitumor immunity. Hence, APAP should be used with caution in patients treated with ICB.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: Updated Analysis from the Phase 2 KEYNOTE-158 Study.\r\n Pembrolizumab demonstrated clinically meaningful and durable benefit, with high ORR of 30.8%, long median duration of response of 47.5 months, and manageable safety across a range of heavily pretreated, advanced MSI-H/dMMR noncolorectal cancers, providing support for use of pembrolizumab in this setting.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Anticoagulation in Hospitalized Patients with COVID-19.\r\nThree randomized control trials suggesting benefit of therapeutic heparin in hospitalized non-critically ill patients with COVID-19 have led to conditional guideline recommendations for this treatment. By contrast, prophylactic dose heparin is recommended for critically ill patients. Unprecedented collaboration and rapidly funded research has improved care of hospitalized patients with COVID-19.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nComparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.\r\nThe ORR and CR rate were 49.9% and 29.9% in SCHOLAR-5 compared to 94.2% and 79.1% in ZUMA-5, for odds ratios of 16.2 (95%CI: 5.6-46.9) and 8.9 (95%CI: 4.3-18.3). Compared to available therapies, axi-cel demonstrated an improvement in meaningful clinical endpoints. This study suggests axi-cel may address an important unmet need for r/r FL patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHemolysis, free hemoglobin toxicity and scavenger protein therapeutics.\r\nPathological hemolysis outpaces macrophage capacity and scavenger synthesis across a diversity of diseases. This imbalance leads to hemoglobin-driven disease progression. To meet a void in treatment options, scavenger protein-based therapeutics are in clinical development.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHow I Treat Immune Mediated Thrombotic Thrombocytopenic Purpura After Hospital Discharge.\r\nThere is both the risk of relapse and long-term complications that include neurocognitive deficits and cardiovascular events in remission that occur in patients after recovery from an acute iTTP episode. Data on the risk factors for the development of these complications, the appropriate screening, and treatment of these complications is limited due to the paucity of research. In this article, we review the current understanding on the risk factors for exacerbation, relapse, and long-term complications of iTTP, and discuss our approach in following iTTP patients after hospital discharge and during the long-term follow-up in the outpatient setting.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIL-1b expression in bone marrow dendritic cells is induced by TLR2 agonists and regulates HSC function.\r\nSingle cell RNA sequencing of low risk MDS bone marrow show that IL1B and TLR1 expression is increased in DCs. Collectively, these data suggest a model in which TLR1/2 stimulation of DCs induces secretion of IL-1b and other inflammatory cytokines into the perivascular niche, which in turn, regulates multipotent HSPCs. Increased DC TLR1/2 signaling may contribute to altered HSPC function in MDS by increasing local IL-1b expression.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOutcomes Following Treatment for Adenosine Deaminase Deficient Severe Combined Immunodeficiency: A Report from the PIDTC.\r\nFive-year EFS (90.5%) and OS (100%) were best for matched sibling and matched family donors (MSD/MFD). For patients treated after the year 2000 and without active infection at the time of FDCT, no difference in 5-year EFS or OS was found between HCT using a variety of transplant approaches and ERT-GT. This suggests alternative donor HCT may be considered when MSD/MFD HCT and GT are not available, particularly when newborn screening identifies ADA-SCID patients soon after birth and before the onset of infections.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\np57Kip2 regulates embryonic blood stem cells by controlling sympathoadrenal progenitor expansion.\r\nTo gain further molecular insights, we have generated a single-cell RNA-Seq dataset of al Ngfr+ sympathoadrenal cells around the dorsal aorta to dissect their differentiation pathway. Importantly, this not only defined the relevant p57Kip2-expressing SNS progenitor stage, but also revealed that some neural crest cells, upon arrival at the aorta, are able to take an alternative differentiation pathway, giving rise to a subset of ventrally restricted mesenchymal cells that express important HSC-supportive factors. Neural crest cells thus appear to contribute to the AGM HSC niche via two different mechanisms: SNS-mediated catecholamine secretion and HSC-supportive mesenchymal cell production.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nProphylactic tranexamic acid in patients with hematologic malignancy: a placebo controlled, randomized clinical trial.\r\nMost common adverse events were: diarrhea [(116/164 (70.7%) TXA and 114/163 (69.9%) placebo)];  febrile neutropenia [111/164 (67.7%) TXA, 105/163 (64.4%) placebo];  fatigue [106/164 (64.6%) TXA, 109/163 (66.9%) placebo];  and nausea [104/164 (63.4%) TXA, 97/163 (59.5%) placebo]. Among patients with hematologic malignancy undergoing chemotherapy or hematopoietic stem cell transplantation, prophylactic treatment with tranexamic acid compared with placebo did not significantly reduce the risk of WHO grade 2 or higher bleeding. Trial Registration:  Identifier: NCT02578901.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRecurrent non-coding somatic and germline WT1 variants converge to disrupt MYB binding in acute promyelocytic leukemia.\r\nThe high incidence of biallelic inactivation suggested the tumor suppressor activity of WT1 in APL. Mechanistically, non-coding WT1 variants disrupted MYB binding on chromatin and suppressed the enhancer activity and WT1 expression through destroying the chromatin looping formation. Our study highlights the essential role of non-coding variants in the leukemogenesis of APL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRole of Allogeneic Transplantation In Chronic Myelomonocytic Leukemia: An International Collaborative Analysis.\r\nIn a multivariable analysis of lower-risk patients, performing allo-HCT before transformation to AML significantly increased the risk of death within two years of transplantation (HR=3.19, 95%CI 2.30-4.42, P<0.001), with no significant change in long-term survival beyond this time point (HR=0.98, 95%CI 0.58-1.64, P=0.92). In higher risk patients, allo-HCT significantly increased the risk of death in the first two years after transplant (HR=1.46, 95%CI 1.09-1.96, P=0.01), but not beyond (HR=0.60, 95%CI 0.34-1.08, P=0.09). Performing allo-HCT before AML transformation decreases life expectancy in lower risk patients but may be considered in higher risk patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.\r\nThis superior OS was determined independent of blast count, abnormal karyotypes, and concurrent variants, including TP53 in AML/MDS patients, regardless of patient's sex, age or specific germline CV, suggesting that germline DDX41 variants define a distinct clinical entity. Furthermore, unrelated patients with myeloproliferative neoplasm (MPN) and B-cell lymphoma were linked by DDX41 CV, thus expanding the known disease spectrum. This study outlines the CV landscape, expands the phenotypic spectrum in unrelated DDX41-mutated patients, and underscores the urgent need for gene-specific diagnostic and clinical management guidelines.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe Impact of T cell Immunity on Chemotherapy Response in Childhood Acute Lymphoblastic Leukemia.\r\nConsistent with these observations, IFNG and IL12 directly modulated dasatinib anti-leukemia efficacy in vivo. Finally, we evaluated peripheral blood immune cell composition in 102 children with ALL during chemotherapy and observed a significant association of T cell abundance with treatment outcomes. Together, these results suggest that T cell immunity plays pivotal roles in maintaining long-term remission of ALL, highlighting that the interplay between host immunity and drug resistance can be harnessed to improve ALL chemotherapy outcomes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia.\r\nIn contrast, argatroban showed no effect on procoagulant platelets and aggregation but significantly inhibited VITT-mediated thrombus formation. Taken together, our data indicate that negatively charged anticoagulants can disrupt VITT-Ab/PF4 interactions, which might serve as an approach to reduce Ab-mediated complications in VITT. Our results should be confirmed, however, in a clinical setting before a recommendation regarding the selection of anticoagulants in VITT patients could be made.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nUnique characteristics of lung resident neutrophils are maintained by PGE2/PKA/Tgm2-mediated signaling.\r\nNeutrophils from Tgm2-/- mice release high levels of inflammatory cytokines in response to LPS. Lung damage is significantly exacerbated in Tgm2-/- mice in an LPS-induced acute respiratory distress syndrome model. Collectively, we demonstrate that prostaglandin E2 is a key factor for the generation of LNs with unique immune suppressive characteristics, acting through protein kinase A and Tgm2, and LNs play essential roles in the protection of the lungs against pathogenic inflammation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nVaccine-induced immune thrombotic thrombocytopenia (VITT) is mediated by a stereotyped clonotypic antibody.\r\nMoreover, striking stereotypic features were also identified in heavy-chains anti-PF4 antibodies characterised by identical HCDR3 length and homologous sequences. In summary, we unravelled the molecular signature of highly stereotyped clonotypic anti-PF4 antibodies, indicating shared pathways of antibody production in VITT patients. These discoveries are critical to understand the molecular basis of this serious condition and develop novel therapies aimed at removing pathogenic clones.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia.\r\nSLC7A11 was also one of only 2.4% of LASP response genes with basal level gene expression that also correlated with LASP ex vivo resistance in primary leukemia cells. Experiments using chemical inhibition of SLC7A11 with sulfasalazine, gene overexpression, and partial gene knockout recapitulated LASP resistance or sensitivity in ALL cell lines. These findings show the importance of assessing changes in gene expression following treatment with an antileukemic agent for its association with drug resistance and highlight that many response genes may not differ in their basal expression in drug-resistant leukemia cells.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDeveloping and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study.\r\nBoth calibration plots illustrated a high degree of consistency in the estimated and observed risk. In addition, the decision curve analysis showed a considerable net benefit for patients. Thus, an application (47.94.162.105:8080/ich/) was established for users to predict 30-day mortality when ICH occurred in adult patients with ITP.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nETS1 is a novel transcriptional regulator of adult T-cell leukemia/lymphoma of North American descent.\r\nCCR4, a previously identified oncogenic factor in ATLL was found to be a direct ETS1 transcriptional target in NA-ATLL. As such, ETS1 provides an alternate mechanism to enhance CCR4 expression/activity in NA-ATLL, even in the absence of activating CCR4 mutations (CCR4 mutations were identified in 4 of 9 NA-ATLL cases). Taken together, this study identifies ETS1 as a novel dominant oncogenic transcriptional regulator in NA-ATLL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIn vivo HSC transduction in rhesus macaques with an HDAd5/3+ vector targeting desmoglein 2 and transiently over-expressing cxcr4.\r\nIn vivo transduction with a HDAd5/3+GFP/cxcr4 vector at a low dose of 0.4x1012vp/kg resulted in up to 7% of GFP-positive CD34+/CD45RA-/CD90+ cells in the bone marrow. This transduction rate is a solid basis for in vivo base or prime editing in combination with natural or drug-induced expansion of edited HSCs. Furthermore, our study provides new insights into HSC biology and trafficking after mobilization in non-human primates.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLinked-read whole-genome sequencing resolves common and private structural variants in multiple myeloma.\r\nIn addition, we identified private SVs causing the dysregulation of genes recurrently involved in translocations with the IGH locus and show that these can alter the molecular classification of the MM. Overall, we conclude that lrWGS allows for the detection of aberrations critical for MM prognostics and provides a feasible route for providing comprehensive genetics. Implementing lrWGS could provide more accurate clinical prognostics, facilitate genomic medicine initiatives, and greatly improve the stratification of patients included in clinical trials.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNurse-like cells sequester B cells in chronic lymphocytic leukemia disorganized lymph nodes via an alternative production of CCL21.\r\nOur results indicate NLCs as providers of an alternative source of CCL21, taking over the physiological task of follicular reticular cells (FRCs) whose network is deeply altered in CLL lymph nodes. Moreover, CCL21, by retaining malignant B cells, provide a protective environment for their niching and survival thus allowing immune tumor survey evasion and resistance to treatment. These findings argue for a specific targeting or re-education of NLCs as a new immunotherapy strategy for this still deadly disease.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPonatinib, Chemotherapy, and Transplant in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.\r\nThe combination of chemotherapy with ponatinib followed by alloHSCT is well tolerated, with encouraging EFS in adults with newly diagnosed Ph+ALL. Cross-trial comparison suggests improvement versus imatinib. ( NCT02776605).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPredicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism.\r\nIncidence of major bleeding events per 100 person-years in high- and non-high-risk patients, respectively, were 3.9 (95% confidence interval, 3.0-5.1) and 1.1 (0.8-1.4) using the newly derived CHAP model (creatinine, hemoglobin, age, and use of antiplatelet agent), 3.3 (2.6-4.1) and 1.0 (0.7-1.3) using modified ACCP, 5.3 (0.6-19.2) and 1.7 (1.4-2.0) using modified RIETE, 3.1 (2.3-3.9) and 1.1 (0.9-1.5) using modified VTE-BLEED, 5.2 (3.3-7.8) and 1.5 (1.2-1.8) using modified HAS-BLED, and 4.8 (1.3-12.4) and 1.7 (1.4-2.0) using modified OBRI scores. Modified versions of the ACCP, VTE-BLEED, and HAS-BLED scores help identify patients with unprovoked VTE who are at high risk of major bleeding and should be considered for discontinuation of anticoagulation after 3-6 months of initial treatment. The CHAP model may further improve estimation of bleeding risk by using continuous predictor variables, but external validation is required before its implementation in clinical practice.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nProspective external validation of biomarkers to predict acute graft-versus host disease severity.\r\nIn addition to clinical variables, biomarkers slightly improved the prediction of overall survival and NRM (concordance [C] and net reclassification indexes). The potential benefit of adding biomarkers panel to clinical parameters was also investigated by decision curve analyses. The benefit of adding biomarkers to clinical parameters was however marginal for the D28 non-response and mortality endpoints.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPUM1 mediates the posttranscriptional regulation of human fetal hemoglobin.\r\nKnockdown of PUM1 leads to a robust increase in fetal hemoglobin (~22% HbF), without affecting ÃŸ-globin levels in human erythroid cells. Importantly, targeting PUM1 does not limit erythropoiesis progression, providing a potentially safe and effective treatment strategy in sickle cell anemia and ÃŸ-thalassemia. In support of this idea, we report elevated fetal hemoglobin levels in the absence of anemia, in an individual with a novel heterozygous PUM1 mutation in the RNA binding domain (p.(His1090Profs*16);  c.3267_3270delTCAC), suggesting that PUM1 mediated post-transcriptional regulation is a critical player during human hemoglobin switching.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRisk of diabetes and the impact on preexisting diabetes in lymphoma patients treated with steroid-containing immunochemotherapy.\r\nIn a landmark analysis at one year, DM patients with lymphoma had decreased risks of insulin dependency compared to comparators. Time-varying IRRs showed a higher CVD risk for NHL patients with DM as compared to comparators in the first year after treatment. NHL patients treated with steroid-containing immunochemotherapy regimens have a clinically insignificant increased risk of DM in the first year following treatment, and patients with pre-existing DM have a temporary increased risk of insulin prescriptions and CVD.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSingle-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma.\r\nThis is the first study to integrate tumor mutational profiling, cell of origin classification, and multiplexed immuno-phenotyping of the TME into a spatial analysis of DLBCL at the single cell level. We demonstrate that, far from being histo-pathologically monotonous, DLBCL has a complex tumor architecture, and that changes in tumor topology can be correlated with clinically relevant features. This analysis identifies candidate biomarkers and therapeutic targets such as TIM-3, CCR4, and CXCR3 that are relevant for combination treatment strategies in immuno-oncology and cellular therapies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSynonymous ADAMTS13 variants impact molecular characteristics and contribute to variability in active protein abundance.\r\nUsing various prediction tools of biomolecular characteristics, we evaluated al ADAMTS13 sSNVs registered in the NCBI dbSNP, including 357 neutral sSNVs and 19 sSNVs identified in TTP patients. We showed that some sSNVs change mRNA folding energy/stability, disrupt mRNA splicing, disturb micro RNAs (miRNAs) binding sites, and alter synonymous codon or codon pair usage. Our findings highlight the importance of considering sSNVs when assessing the complex effects of ADAMTS13 alleles and our approach provides a generalizable framework to characterize sSNV impact in other genes and diseases.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nUpregulated SPAG6 promotes acute myeloid leukemia progression through MYO1D that regulates the EGFR family expression.\r\nSpecifically, overexpression of SPAG6 promoted the translocation of MYO1D into the cell membrane, thus upgrading the expression level of the EGFR family and thereby promoting the progression of AML. Overall, our study found that SPAG6 combined with MYO1D and translocated MYO1D from the cytosol to the cytomembrane, which induced the PI3K/AKT signaling and ERK signaling pathway to regulate the growth and prognosis of AML. SPAG6 may become a new target gene for the treatment of AML.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.\r\nAn Andersen-Gill regression model on OS revealed ELN favorable-risk (HR, 0.34;  P=0.006) and trisomy 4 as sole abnormality (HR, 0.41 P=0.01) as favorable factors, whereas age with a difference of ten years (HR, 1.15, P=0.11), female gender (OR, 0.74;  P=0.20) and allo-HCT (OR, 0.64;  P=0.14) had no significant impact. In our cohort, patients with trisomy 4 as a sole abnormality had a high CR rate and favorable clinical outcome. Allo-HCT seems not to improve OS.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDaratumumab for treatment-refractory acquired idiopathic pure red cell aplasia.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPET-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T-cells.\r\nResponse at M3 evaluated in 90 (57%) patients was prognostic for PFS with lower discrimination (HR=3.28 (95%CI: 1.5-7.0), p=0.003) but did not predict OS (HR = 0.61 (95%CI: 0.2-2.3) p=0.45). Patients with high baseline total metabolic tumor volume (TMTV) >80ml had worse PFS (HR=2.05 (95%CI: 1.2-3.5), p=0.009) and OS (HR=4.52 (95%CI: 2.5-8.1), p80ml, and DS-5 at M1 for OS. In conclusion, baseline TMTV and response at M1 strongly predicts outcomes of patients with R/R LBCL undergoing CAR T-cells.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Integrated proteogenomic characterization of urothelial carcinoma of the bladder.\r\nThis study provides a valuable resource for researchers and clinicians to further identify molecular pathogenesis and therapeutic opportunities in urothelial carcinoma of the bladder.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nLancet Haematol\r\n    Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial.\r\nFurther controlled clinical trials are warranted to confirm these results. Funding Instituto de Salud Carlos III and the European Regional Development Fund. Translation For the Spanish translation of the abstract see Supplementary Materials section.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL.\r\nInvestigation of metabolism in vitro and in vivo supported these findings, revealing reduced aerobic glycolysis and increased basal respiration in CD147 knockdown. In conclusion, our findings indicate that CD147 is of vital importance for ALK+ ALCL to maintain the high energy demand of rapid cell proliferation, promoting lactate export, and tumor growth. Furthermore, CD147 has the potential to serve as a novel therapeutic target in ALK+ ALCL, and warrants further investigation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEvolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia.\r\nA total of 27 eligibility criteria were used across trials, mostly concerning comorbidities or performance status, with eight of them becoming more common over time. The concordance with recent ASCO - Friends of Cancer Research eligibility criteria recommendations greatly varied, from 35% to 99%. Together, our analyses suggest that the ability to generalize results from non-transplant RCTs may be increasingly limited because of high non-enrollment rates and increasingly restrictive eligibility criteria.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHistone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms.\r\nThese findings led to reduced disease penetrance and improved survival in xenograft models of human JAK2-mutated cells. KDM4C deleted cells showed alterations in target histone residue methylation and target gene expression, resulting in induction of cellular senescence. In summary, these data establish KDM4C as a specific dependency and therapeutic target in JAK2-mutated cells that is essential for oncogenic signaling and prevents induction of senescence.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImpact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.\r\nThis subtle difference led to measurable transcript-type dependent variation in estimates of residual disease which could be corrected by (i) taking the qPCR amplification efficiency into account, (ii) using alternative RT-qPCR approaches or (iii) droplet digital PCR (ddPCR), a technique which is relatively insensitive to differences in amplification kinetics. In CML patients, higher levels of BCR::ABL1/GUSB were identified at diagnosis for patients expressing e13a2 (n=67) compared to e14a2 (n=78) when analysed by RT-qPCR (P=0.0005) but not ddPCR (P=0.5). These data indicate that widely used RT-qPCR assays result in subtly different estimates of disease depending on BCR::ABL1 transcript type;  these differences are small but may need to be considered for optimal patient management.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNovel mitochondria-targeting compounds selectively kill human leukemia cells.\r\nThese compounds exhibited synergy with several anti-leukemia agents in AML, acute lymphoblastic leukemia (ALL), or chronic myelogenous leukemia (CML). Pilot in vivo efficacy studies indicate anti-leukemic efficacy in a MOLM14/GFP/LUC xenograft model, including extended survival in mice injected with leukemic cells pre-treated with PS127B or PS127E and in mice treated with PS127E at a dose of 5mg/kg. These compounds are promising leads for development of future combinatorial therapeutic approaches for mitochondria-driven hematologic malignancies such as AML, ALL, and CML.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Point of Care Assessment of Direct Oral Anticoagulation in Acute Ischemic Stroke: Protocol for a Prospective Observational Diagnostic Accuracy Study.\r\n Viscoelastic point-of-care assessment of clotting time in whole blood might improve swift delivery of time-sensitive hyperacute treatment with IVT in stroke patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nReviews&Editorials\r\nPlenty of the editorials are available as full text through the publisher website using the provided link\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#gecndjtnip .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#gecndjtnip .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#gecndjtnip .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#gecndjtnip .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#gecndjtnip .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#gecndjtnip .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#gecndjtnip .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#gecndjtnip .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#gecndjtnip .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#gecndjtnip .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#gecndjtnip .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#gecndjtnip .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#gecndjtnip .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#gecndjtnip .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#gecndjtnip .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#gecndjtnip .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#gecndjtnip .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#gecndjtnip .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#gecndjtnip .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#gecndjtnip .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#gecndjtnip .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#gecndjtnip .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#gecndjtnip .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#gecndjtnip .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#gecndjtnip .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#gecndjtnip .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#gecndjtnip .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#gecndjtnip .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#gecndjtnip .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#gecndjtnip .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#gecndjtnip .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#gecndjtnip .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#gecndjtnip .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#gecndjtnip .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#gecndjtnip .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood\r\n    A CAPTIVATE-ing new regimen for CLL.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDefending the island against excess heme.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nExtramedullary hematopoietic stem cells.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHeparin or nonheparin anticoagulants for VITT.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nHyperuricemia reduces neutrophil function.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIntroduction to a Review Series on COVID-19.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nLinking epigenome regulation with DNA repair.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nQuenching the cytokine fire in the lungs.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Resistance to targeted therapies: delving into FLT3 and IDH.\r\nRecent advances in FLT3 and IDH targeted inhibition have improved response rates and overall survival in patients with mutations affecting these respective proteins. Despite this success, resistance mechanisms have arisen including mutations that disrupt inhibitor-target interaction, mutations impacting alternate pathways, and changes in the microenvironment. Here we review the role of these proteins in leukemogenesis, their respective inhibitors, mechanisms of resistance, and briefly ongoing studies aimed at overcoming resistance.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCA Cancer J Clin\r\n    Oncologic emergencies and urgencies: A comprehensive review.\r\nEmergent and urgent complications associated with targeted therapeutics, including small molecules, naked and drug-conjugated monoclonal antibodies, as well as immune checkpoint inhibitors and chimeric antigen receptor T-cells, are summarized. Finally, strategies for facilitating same-day direct admission to hospice from the ED are discussed. This article not only can serve as a point-of-care reference for the ED physician but also can assist outpatient oncologists as well as inpatient hospitalists in coordinating care around the ED visit.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination.\r\nVenetoclax is active in other lymphoid malignancies including several B cell non-Hodgkin lymphomas, acute lymphoblastic leukemia and multiple myeloma, with the highest intrinsic sensitivity observed in mantle cell lymphoma and Waldenstrom macroglobulinemia. Venetoclax combination with standard regimens in follicular lymphoma, multiple myeloma and aggressive B cell neoplasms has shown some promise, but further studies are required to optimize dose and scheduling to mitigate increased myelosuppression and infection risk, and to find validated biomarkers of venetoclax sensitivity. Future research will focus on overcoming venetoclax resistance, targeting other BCL2 family members and the rational design of synergistic combinations.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nHow we treat NK/T-cell lymphomas.\r\nAutologous HSCT does not improve outcome. In relapsed/refractory cases, novel approaches comprise immune checkpoint blockade of PD1/PD-L1, EBV-specific cytotoxic T-cells, monoclonal antibodies, and histone deacetylase inhibitors. Future strategies may include inhibition of signalling pathways and driver mutations, and immunotherapy targeting the lymphoma and its microenvironment.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nHypoxia-inducible factors: master regulators of hypoxic tumor immune escape.\r\nOverall, elucidating the underlying mechanisms by which HIFs promote evasion of tumor immune surveillance will allow for targeting HIF in tumor treatment. This review discusses the current knowledge of how hypoxia and HIFs facilitate tumor immune escape, with evidence to date implicating HIF1A as a molecular target in such immune escape. This review provides further insight into the mechanism of tumor immune escape, and strategies for tumor immunotherapy are suggested.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nPatient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?\r\nStudies suggest that the early use of immunotherapy may improve outcomes significantly. In this review, we summarize the currently available clinical literature on CAR and BiTE in MM. Furthermore, we will compare these two T cell-based immunotherapies and discuss potential therapeutic approaches to promote development of new clinical trials, using T cell-based immunotherapies, even as bridging therapies to a transplant.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    Sickle cell disease: a year in review.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations.\r\nBecause of the large inter-individual variations in MTX/6-MP bioavailability and metabolism, dose adjustments are traditionally guided by the degree of myelosuppression, but this does not accurately reflect treatment intensity. DNA-TG is a common downstream metabolite of MTX/6-MP combination chemotherapy, and a higher level of DNA-TG has been associated with a lower relapse hazard, leading to the development of the Thiopurine Enhanced ALL Maintenance (TEAM) strategy-the addition of low-dose (2.5-12.5mg/m 2 /day) 6-thioguanine to the 6-MP/MTX backbone-that is currently being tested in a randomized ALLTogether1 trial (EudraCT: 2018-001795-38). Mutations in the thiopurine and MTX metabolism pathways, and in the mismatch repair genes have been identified in early ALL relapses, providing valuable insights to assist the development of strategies to detect imminent relapse, to facilitate relapse salvage therapy, and even to bring about changes in frontline ALL therapy to mitigate this relapse risk.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRelapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies.\r\nAnother major barrier to improvement in outcomes for relapsed pediatric AML is the historic lack of availability and participation in clinical trials. There are ongoing efforts to launch multinational clinical trials of emerging therapies. The purpose of this review is to summarize currently available and newly developed therapies for relapsed pediatric AML.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nLetters&Replies\r\nLetters to the editors and authorsâ€™ replies\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#erlgnmkkxh .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#erlgnmkkxh .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#erlgnmkkxh .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#erlgnmkkxh .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#erlgnmkkxh .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#erlgnmkkxh .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#erlgnmkkxh .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#erlgnmkkxh .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#erlgnmkkxh .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#erlgnmkkxh .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#erlgnmkkxh .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#erlgnmkkxh .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#erlgnmkkxh .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#erlgnmkkxh .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#erlgnmkkxh .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#erlgnmkkxh .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#erlgnmkkxh .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#erlgnmkkxh .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#erlgnmkkxh .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#erlgnmkkxh .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#erlgnmkkxh .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#erlgnmkkxh .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#erlgnmkkxh .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#erlgnmkkxh .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#erlgnmkkxh .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#erlgnmkkxh .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#erlgnmkkxh .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#erlgnmkkxh .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#erlgnmkkxh .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#erlgnmkkxh .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#erlgnmkkxh .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#erlgnmkkxh .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#erlgnmkkxh .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#erlgnmkkxh .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#erlgnmkkxh .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood Cancer J\r\n    ATM germline variants in a young adult with chronic lymphocytic leukemia: 8years of genomic evolution.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nClinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nPotential role of STAG1 mutations in genetic predisposition to childhood hematological malignancies.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nJ Hematol Oncol\r\n    DTX-P7, a peptide-drug conjugate, is highly effective for non-small cell lung cancer.\r\nMore importantly, we found that DTX-P7 promoted cell cycle reentry of slow-proliferating CSLCs and subsequently killed them, exhibiting a \"proliferate to kill\" pattern. Collecitvely, by force of active targeting delivery of DTX via membrane-bound Hsp90, DTX-P7 induces unfolded protein response and subsequent apoptosis by degrading Hsp90, meanwhile awakens and kills the dormant cancer stem cells. Thus, DTX-P7 deserves further development as a promising anticancer therapeutic for treatment of various membrane-harboring Hsp90 cancer types.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nMammary adipocytes protect triple-negative breast cancer cells from ferroptosis.\r\nMechanistically, oleic acid secreted from adipocytes inhibited lipid peroxidation and ferroptosis of triple-negative breast cancer cells in the presence of ACSL3. Taken together, mammary adipocytes can protect breast cancer cells from ferroptosis through oleic acid in the presence of ACSL3. These findings could provide new ideas and targets for tumor treatment.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nLancet Haematol\r\n    Prehospital blood transfusion for haemorrhagic shock - Authors' reply.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPrehospital blood transfusion for haemorrhagic shock.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPrehospital blood transfusion for haemorrhagic shock.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPrehospital blood transfusion for haemorrhagic shock.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nOthers\r\nall remaining publications eg case reports, images of the month, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#vystnuksch .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#vystnuksch .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vystnuksch .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#vystnuksch .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#vystnuksch .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#vystnuksch .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vystnuksch .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#vystnuksch .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#vystnuksch .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#vystnuksch .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#vystnuksch .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#vystnuksch .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#vystnuksch .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#vystnuksch .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#vystnuksch .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#vystnuksch .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#vystnuksch .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#vystnuksch .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#vystnuksch .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#vystnuksch .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#vystnuksch .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#vystnuksch .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#vystnuksch .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#vystnuksch .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vystnuksch .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#vystnuksch .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vystnuksch .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#vystnuksch .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#vystnuksch .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#vystnuksch .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#vystnuksch .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#vystnuksch .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#vystnuksch .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#vystnuksch .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#vystnuksch .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood\r\n    Extranodal natural killer/T-cell lymphoma of the palate.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHenden AS, Koyama M, Robb RJ, etÂ al. IFN- therapy prevents severe gastrointestinal graft-versus-host disease. Blood. 2021;138(8):722-737.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSclerosing extramedullary hematopoietic tumor in chronic myeloproliferative neoplasms.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nYu Z, Yang W, He X, etÂ al. Endothelial cell-derived angiopoietin-like protein 2 supports hematopoietic stem cell activities in bone marrow niches. Blood. 2022;139(10):1529-1540.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Racial Disparities in Access to Alternative Donor Allografts Persist in the Era of \"Donors for All\".\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    A curious case of a neutrophilic horn.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBedside art is good medicine.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFuture role of topical pimecrolimus in early stage mycosis fungoides?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Remodeling of the m6A RNA landscape in the conversion of acute lymphoblastic leukemia cells to macrophages.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n// add bootstrap table styles to pandoc tables\r\nfunction bootstrapStylePandocTables() {\r\n  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');\r\n}\r\n$(document).ready(function () {\r\n  bootstrapStylePandocTables();\r\n});\r\n\r\n\r\n\r\n$(document).ready(function () {\r\n  window.buildTabsets(\"TOC\");\r\n});\r\n\r\n$(document).ready(function () {\r\n  $('.tabset-dropdown > .nav-tabs > li').click(function () {\r\n    $(this).parent().toggleClass('nav-tabs-open');\r\n  });\r\n});\r\n\r\n  (function () {\r\n    var script = document.createElement(\"script\");\r\n    script.type = \"text/javascript\";\r\n    script.src  = \"https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML\";\r\n    document.getElementsByTagName(\"head\")[0].appendChild(script);\r\n  })();\r\n\r\n\r\n\r\n\r\n\r\n",
    "preview": {},
    "last_modified": "2022-06-13T07:17:19-04:00",
    "input_file": {}
  },
  {
    "path": "hema/06-03-2022/",
    "title": "Fri Jun 03 2022",
    "description": "75 articles - From Friday May 27 2022 to Friday Jun 03 2022",
    "author": [],
    "date": "2022-06-03",
    "categories": [],
    "contents": "\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nparm_toc.knith1 {font-size: 34px;}\r\n       h1.title {font-size: 38px;}\r\n       h2 {font-size: 30px;}\r\n       h3 {font-size: 24px;}\r\n       h4 {font-size: 18px;}\r\n       h5 {font-size: 16px;}\r\n       h6 {font-size: 12px;}\r\n       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}\r\n       pre:not([class]) { background-color: white }\r\n  code{white-space: pre-wrap;}\r\n  span.smallcaps{font-variant: small-caps;}\r\n  span.underline{text-decoration: underline;}\r\n  div.column{display: inline-block; vertical-align: top; width: 50%;}\r\n  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\r\n  ul.task-list{list-style: none;}\r\n    code{white-space: pre;}\r\nif (window.hljs) {\r\n  hljs.configure({languages: []});\r\n  hljs.initHighlightingOnLoad();\r\n  if (document.readyState && document.readyState === \"complete\") {\r\n    window.setTimeout(function() { hljs.initHighlighting(); }, 0);\r\n  }\r\n}\r\n\r\n.main-container {\r\n  max-width: 940px;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n}\r\nimg {\r\n  max-width:100%;\r\n}\r\n.tabbed-pane {\r\n  padding-top: 12px;\r\n}\r\n.html-widget {\r\n  margin-bottom: 20px;\r\n}\r\nbutton.code-folding-btn:focus {\r\n  outline: none;\r\n}\r\nsummary {\r\n  display: list-item;\r\n}\r\npre code {\r\n  padding: 0;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs {\r\n  display: inline-table;\r\n  max-height: 500px;\r\n  min-height: 44px;\r\n  overflow-y: auto;\r\n  border: 1px solid #ddd;\r\n  border-radius: 4px;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {\r\n  content: \"<U+E258>\";\r\n  border: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active {\r\n  display: block;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li > a,\r\n.tabset-dropdown > .nav-tabs > li > a:focus,\r\n.tabset-dropdown > .nav-tabs > li > a:hover {\r\n  border: none;\r\n  display: inline-block;\r\n  border-radius: 4px;\r\n  background-color: transparent;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li {\r\n  display: block;\r\n  float: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li {\r\n  display: none;\r\n}\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nGuidelines\r\nMeta-analysis\r\nOriginal articles\r\nReviews&Editorials\r\nLetters&Replies\r\nOthers\r\n\r\n\r\n\r\n$(function () {\r\n          $('#goTop').goTop({\"container\":\"\",\"appear\":200,\"scrolltime\":800,\"src\":\"fas fa-chevron-up\",\"width\":45,\"place\":\"left\",\"color\":\"\",\"fadein\":500,\"fadeout\":500,\"opacity\":0.5,\"marginX\":2,\"marginY\":2,\"zIndex\":9});\r\n         });\r\nGuidelines\r\nGuidelines, position statements, white papers, technical reviews, consensus statements, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#armsffuhit .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#armsffuhit .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#armsffuhit .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#armsffuhit .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#armsffuhit .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#armsffuhit .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#armsffuhit .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#armsffuhit .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#armsffuhit .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#armsffuhit .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#armsffuhit .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#armsffuhit .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#armsffuhit .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#armsffuhit .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#armsffuhit .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#armsffuhit .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#armsffuhit .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#armsffuhit .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#armsffuhit .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#armsffuhit .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#armsffuhit .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#armsffuhit .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#armsffuhit .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#armsffuhit .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#armsffuhit .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#armsffuhit .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#armsffuhit .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#armsffuhit .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#armsffuhit .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#armsffuhit .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#armsffuhit .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#armsffuhit .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#armsffuhit .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#armsffuhit .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#armsffuhit .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood\r\n    The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. \r\nMajor findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification (ICC) of mature lymphoid, histiocytic, and dendritic cell tumors.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMeta-analysis\r\nmeta-analyses and systematic reviews\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#lqunqfqsiv .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#lqunqfqsiv .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lqunqfqsiv .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#lqunqfqsiv .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#lqunqfqsiv .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#lqunqfqsiv .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lqunqfqsiv .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#lqunqfqsiv .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#lqunqfqsiv .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#lqunqfqsiv .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#lqunqfqsiv .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#lqunqfqsiv .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#lqunqfqsiv .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#lqunqfqsiv .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#lqunqfqsiv .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#lqunqfqsiv .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#lqunqfqsiv .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#lqunqfqsiv .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#lqunqfqsiv .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#lqunqfqsiv .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#lqunqfqsiv .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#lqunqfqsiv .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#lqunqfqsiv .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#lqunqfqsiv .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lqunqfqsiv .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#lqunqfqsiv .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lqunqfqsiv .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#lqunqfqsiv .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#lqunqfqsiv .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#lqunqfqsiv .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#lqunqfqsiv .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#lqunqfqsiv .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#lqunqfqsiv .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#lqunqfqsiv .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#lqunqfqsiv .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood Cancer J\r\n    Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review.\r\nSimilarly, AEs were rarely reported (0-50.9% =1 AE, 0-7.5% =1 serious AE). In conclusion, HM patients present impaired humoral and cellular immune response to COVID-19 vaccination with disease and treatment specific response patterns. In light of the ongoing pandemic with the easing of mitigation strategies, new approaches to avert severe infection are urgently needed for this vulnerable patient population that responds poorly to current COVID-19 vaccine regimens.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nOriginal articles\r\nRCT, clinical trials, retrospective studies, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#qxppaxjvnq .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#qxppaxjvnq .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#qxppaxjvnq .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#qxppaxjvnq .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#qxppaxjvnq .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#qxppaxjvnq .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#qxppaxjvnq .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#qxppaxjvnq .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#qxppaxjvnq .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#qxppaxjvnq .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#qxppaxjvnq .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#qxppaxjvnq .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#qxppaxjvnq .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#qxppaxjvnq .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#qxppaxjvnq .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#qxppaxjvnq .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#qxppaxjvnq .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#qxppaxjvnq .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#qxppaxjvnq .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#qxppaxjvnq .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#qxppaxjvnq .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#qxppaxjvnq .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#qxppaxjvnq .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#qxppaxjvnq .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#qxppaxjvnq .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#qxppaxjvnq .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#qxppaxjvnq .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#qxppaxjvnq .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#qxppaxjvnq .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#qxppaxjvnq .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#qxppaxjvnq .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#qxppaxjvnq .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#qxppaxjvnq .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#qxppaxjvnq .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#qxppaxjvnq .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations.\r\nIn a large cohort of underserved patients with cancer, we identified an elevated incidence of CAT with known and novel risk predictors. Hispanics had lower adjusted rates of CAT and mortality. Our findings highlight the need to investigate and incorporate vulnerable populations in clinical trials.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTreosulfan Compared with Reduced-Intensity Busulfan Improves Allogeneic Hematopoietic Cell Transplantation Outcomes of Older Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Final Analysis of a Prospective Randomized Trial.\r\nEFS of patients (median age 60years) was superior after treosulfan compared to RIC busulfan: 36-months-EFS rate 59.5% (95% CI, 52.2 to 66.1) vs 49.7% (95% CI, 43.3 to 55.7) with a hazard ratio (HR) of 0.64 (95% CI, 0.49 to 0.84), P =0.0006. Likewise, overall survival (OS) with treosulfan was superior compared to busulfan: 36-months-OS rate 66.8% vs 56.3%; HR 0.64 (95% CI, 0.48 to 0.87), P = 0.0037. Post hoc analyses revealed that these differences were consistent with the confirmatory interim analysis, and thereby the treosulfan regimen appears particularly suitable for older AML and MDS patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnn Oncol\r\n    Impact of acetaminophen on the efficacy of immunotherapy in cancer patients. \r\nIn addition, interleukin-10, a crucial mediator of Treg-induced immune suppression, was significantly upregulated upon treatment with ICB in cancer patients taking APAP. This study provides strong pre-clinical and clinical evidence of the role of APAP as a potential suppressor of antitumor immunity. Hence, APAP should be used with caution in patients treated with ICB.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nValidation of the Decipher Genomic Classifier in Patients receiving Salvage Radiotherapy without Hormone Therapy after Radical Prostatectomy - An Ancillary Study of the SAKK 09/10 Randomized Clinical Trial.\r\nThis study represents the first contemporary randomized controlled trial in patients treated with early SRT without concurrent hormone therapy or pelvic nodal RT that has validated the prognostic utility of the GC. Independent of standard clinicopathologic variables and RT dose, high-GC patients were more than twice as likely than lower-GC patients to experience biochemical and clinical progression and receive of salvage hormone therapy. This data confirms the clinical value of Decipher GC to personalize the use of concurrent systemic therapy in the postoperative salvage setting.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Anticoagulation in Hospitalized Patients with COVID-19. \r\nThree randomized control trials suggesting benefit of therapeutic heparin in hospitalized non-critically ill patients with COVID-19 have led to conditional guideline recommendations for this treatment. By contrast, prophylactic dose heparin is recommended for critically ill patients. Unprecedented collaboration and rapidly funded research has improved care of hospitalized patients with COVID-19.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T-cells in PTCL-NOS.\r\nFurthermore, stable, ectopic expression of the DNMT3A-mutants in primary CD3+ T-cell cultures resulted in the preferential outgrowth of CD8+ T-cells with DNMT3AR882H mutation. Single-cell-RNA-seq analysis of CD3+ T-cells revealed differential CD8+ T-cell subset polarization, mirroring findings in DNMT3A-mutated PTCL-TBX21 and validating the cytotoxic and T-cell memory transcriptional programs associated with the DNMT3AR882H mutation. Our findings indicate that DNMT3A mutations define a cytotoxic subset in PTCL-TBX21 with prognostic significance, thus may further refine pathological heterogeneity in PTCL-NOS and suggest alternative treatment strategies for this subset.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\np57Kip2 regulates embryonic blood stem cells by controlling sympathoadrenal progenitor expansion. \r\nTo gain further molecular insights, we have generated a single-cell RNA-Seq dataset of al Ngfr+ sympathoadrenal cells around the dorsal aorta to dissect their differentiation pathway. Importantly, this not only defined the relevant p57Kip2-expressing SNS progenitor stage, but also revealed that some neural crest cells, upon arrival at the aorta, are able to take an alternative differentiation pathway, giving rise to a subset of ventrally restricted mesenchymal cells that express important HSC-supportive factors. Neural crest cells thus appear to contribute to the AGM HSC niche via two different mechanisms: SNS-mediated catecholamine secretion and HSC-supportive mesenchymal cell production.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPLAG1 dampens protein synthesis to promote human hematopoietic stem cell self-renewal.\r\nWe find PLAG1 capitalizes on multiple regulatory factors to ensure protective diminished protein synthesis including 4EBP1 and translation-targeting miR-127, and does so independently of stress response signaling. Overall, our study identifies PLAG1 as an enforcer of human HSC dormancy and self-renewal through its highly context-specific regulation of protein biosynthesis, and classifies PLAG1 among a rare set of bona fide regulators of mRNA translation in these cells. Our findings showcase the importance of regulated translation control underlying human HSC physiology, its dysregulation under activating demands, and the potential if its targeting for therapeutic benefit.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRecurrent non-coding somatic and germline WT1 variants converge to disrupt MYB binding in acute promyelocytic leukemia. \r\nThe high incidence of biallelic inactivation suggested the tumor suppressor activity of WT1 in APL. Mechanistically, non-coding WT1 variants disrupted MYB binding on chromatin and suppressed the enhancer activity and WT1 expression through destroying the chromatin looping formation. Our study highlights the essential role of non-coding variants in the leukemogenesis of APL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    A Real-World Study of Combined Modality Therapy for Early-Stage Hodgkin Lymphoma: Too Little Treatment Impacts Outcome.\r\nBased on our real-world experience, CMT appears beneficial for patients with early-stage cHL, especially those with PET2-positive, and unfavorable disease. Chemotherapy-alone regimens can lead to comparable outcomes for patients with favorable, non-bulky, or PET2-negative disease. We conclude that while results seen in clinical trials are replicated in certain patient subgroups, other subgroups not fitting trial criteria do poorly when radiotherapy is excluded.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEfficacy and Safety of Avapritinib in Previously Treated Patients with Advanced Systemic Mastocytosis.\r\nAvapritinib was effective in al AdvSM subtypes, regardless of number/type of prior therapies or somatic mutations associated with poor prognosis. Treatment-related adverse events (TRAEs) were observed in 94% of patients, most commonly grade 1 or 2; 57% had TRAEs =grade 3; 81% remained on treatment at 6 months. Avapritinib in adults with AdvSM who received prior systemic therapy was generally well tolerated with high response rates regardless of prior systemic therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHigh surface IgM levels associate with shorter response to ibrutinib and BTK bypass in CLL patients.\r\nThe residual signaling capacity downstream of BTK was associated with high expression of sIgM, while it was minimal when sIgM expression was low (p<0.05). These results suggested that high sIgM levels facilitated CLL cell resistance to ibrutinib in patients. The CLL cells, surviving in the periphery with high sIgM expression, include a dangerous fraction, able to migrate to tissue and receive proliferative stimuli, which may require targeting by combined approaches.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIdentification and characterization of RBM12 as a novel regulator of fetal hemoglobin expression.\r\nEnhanced crosslinking and immunoprecipitation followed by high throughput sequencing (eCLIP-Seq) revealed strong preferential binding of RBM12 to 5'UTRs of transcripts, narrowing down the mechanism of RBM12 action. Notably, we pinpointed the first of five RRM domains as essential, and, in conjunction with a linker domain, as sufficient for RBM12-mediated HbF regulation. Our characterization of RBM12 as a negative regulator of HbF points to an additional regulatory layer of the fetal-to-adult hemoglobin switch and broadens the pool of potential therapeutic targets for SCD and ÃŸ-thalassemia.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOrgan-specific response after low-dose interleukin-2 therapy for steroid refractory chronic Graft-versus-Host Disease.\r\nFor immunologic correlates, CD4Treg:CD4Tcon ratio at one week was significantly higher in patients with overall and skin response; skin response was significantly associated with lower number of total CD3 T cells, CD4Tcon and CD8 T cells and higher number of B cells. For lung responders, terminal effector memory cell counts were lower within al T cell populations compared to non-responders. Organ-specific mechanisms of injury should be investigated and organ-specific targeted therapies need to be developed.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\np16INK4A dependent senescence in the bone marrow niche drives age-related metabolic changes of hematopoietic progenitors.\r\nWe found that, in response to LPS induced stress, HPC mitochondrial function is impaired and there is a failure to upregulate the TCA cycle in progenitor populations in aged animals compared to young animals. Furthermore, aged mesenchymal stromal cells (MSC) of the BM niche, but not HPCs, exhibit a senescent phenotype and selective depletion of senescent cells from the BM niche, as well as treatment with the senolytic drug ABT-263, improves mitochondrial function of HPCs when stressed with LPS. In summary, age related HPC metabolic dysfunction occurs indirectly as a 'bystander phenomenon' in the aging BM niche and can be restored by targeting senescent MSCs.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe Odyssey of Pacritinib in Myelofibrosis.\r\nAlthough the PERSIST-2 study was terminated abruptly due to this clinical hold, it met its splenic response endpoint and demonstrated a trend towards symptom improvement. Subsequent, diligent review of the PERSIST-1 and PERSIST-2 studies did not confirm an excess of severe bleeding or cardiac events on the pacritinib arm. Additionally, the dose finding PAC203 study endorsed the safety and efficacy of 200 mg twice daily leading to the approval of pacritinib for the treatment of MF patients with platelets =50Ã— 109/L.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.\r\nAmong patients who received a prior FLT3 TKI in ADMIRAL, a higher CRc rate (52%) and trend toward longer median overall survival was observed in the gilteritinib arm versus the SC arm (CRc=20%; overall survival, 5.1 months; HR=0.602; 95% CI: 0.299, 1.210). Remission duration was shorter with prior FLT3 TKI exposure. These findings support gilteritinib for FLT3-mutated R/R AML after prior sorafenib or midostaurin.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nStructural variants shape the genomic landscape and clinical outcome of multiple myeloma.\r\nThese data highlight the heterogeneity of transcriptional dysregulation occurring as a consequence of both the canonical and novel structural variants. Further, it shows that the complex rearrangements chromoplexy, chromothripsis and templated insertions are common in MM with each variant having its own distinct frequency and impact on clinical outcome. Chromothripsis is associated with a significant independent negative impact on clinical outcome in newly diagnosed cases consistent with its use alongside other clinical and genetic risk factors to identify prognosis.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    APOLD1 loss causes endothelial dysfunction involving cell junctions, cytoskeletal architecture, and Weibel-Palade bodies, while disrupting hemostasis.\r\nCompromised vascular integrity resulting from an excess of plasma ANGPT2, and locally impaired availability of VWF may explain the unusual clinical profile of APOLD1:p. R49* patients. In summary, our findings identify APOLD1 as an important regulator of vascular homeostasis and raise the need to consider testing of EC function in patients with IBDs without apparent platelet or coagulation defects.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCytomegalovirus proteins, maternal pregnancy cytokines, and their impact on neonatal immune cytokine profiles and acute lymphoblastic leukemogenesis in children.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHigh-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline.\r\nNotably, among the 16 patients who relapsed, 13 (81%) had a baseline TMTV baseline = 155 mL. Upfront ABVD plus radiation therapy or upfront escBEACOPP without radiotherapy provide similar patient's outcome in high-risk stage IIB HL. TMTV is useful to stratify these patients at baseline.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nInducing synthetic lethality for selective targeting of acute myeloid leukemia cells harboring STAG2 mutations.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLoss of APOLD1: a new vascular bleeding disorder?\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTreatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies.\r\nThrombopoietic growth factors (recombinant human thrombopoietin, pegylated human megakaryocyte growth and development factor, romiplostim, eltrombopag, avatrombopag and hetrombopag) improve pretreatment and nadir platelet counts, reduce the need for platelet transfusions, and enable chemotherapy dose intensity to be maintained. National Comprehensive Cancer Network guidelines permit their use but their widespread adoption awaits adequate phase III randomized, placebo-controlled studies demonstrating maintenance of relative dose intensity, reduction of platelet transfusions and bleeding, and possibly improved survival. Their potential appropriate use also depends on consensus by the oncology community as to what constitutes an appropriate pretreatment platelet count as well as identification of patient-related and treatment variables that might predict bleeding.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial. \r\nFurther controlled clinical trials are warranted to confirm these results. Instituto de Salud Carlos III and the European Regional Development Fund. For the Spanish translation of the abstract see Supplementary Materials section.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.\r\nTreatment-emergent adverse events (TEAEs) were consistent with 12-month data. After 5 years of follow-up there was an increase in the incidence of cardiac, effusion, renal, and vascular TEAEs in bosutinib- and imatinib-treated patients, but overall, no new safety signals were identified. These final results support 400-mg once-daily bosutinib as standard-of-care in patients with newly diagnosed CP CML.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nClonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence.\r\nSingle sample GSEA (ssGSEA) scores of differentially expressed pathways revealed that these changes were most evident in end-stage disease. Increased expression of several potentially targetable genes was found at late disease stages, including cancer-testis antigens, XPO1 and ABC transporters. Our study demonstrates a transcriptomic convergence of pathways supporting increased proliferation and metabolism during disease progression in MM.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nElucidating the importance and regulation of key enhancers for human MEIS1 expression.\r\nWe further show direct binding of FLI1 to the MEIS1 locus in human AML cell lines as well as enrichment of histone acetylation in MEIS1-high healthy and leukemic cells. We also observe a positive correlation between high FLI1 transcript levels and worse overall survival in AML patients. Our study expands the role of ETS factors in AML and our model constitutes a feasible tool for a more detailed understanding of transcriptional regulatory elements and their interactome.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHistone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms. \r\nThese findings led to reduced disease penetrance and improved survival in xenograft models of human JAK2-mutated cells. KDM4C deleted cells showed alterations in target histone residue methylation and target gene expression, resulting in induction of cellular senescence. In summary, these data establish KDM4C as a specific dependency and therapeutic target in JAK2-mutated cells that is essential for oncogenic signaling and prevents induction of senescence.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPredictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy.\r\nMale sex, higher WBC concentration, lower haemoglobin concentration, higher percentage blood blasts and larger spleen size were significantly-associated with lower cumulative incidences of MMR and MR 4 in training dataset. Using Fine-Gray model, we developed the predictive scoring systems for MMR and MR 4 which classified subjects into the low-, intermediate- and high-risk cohorts with significantly-different cumulative incidences of MMR and MR 4 with good predictive discrimination and accuracy in training and validation cohorts with high area under the receiver-operator characteristic curve (AUROC) values. These data may help physicians decide appropriateness of initial imatinib therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRegulation of proton partitioning in kinase-activating acute myeloid leukemia and its therapeutic implication.\r\nCo-inhibition of NHE1 and kinase synergistically acidified pHi in leukemia and inhibited its growth in vivo. Plasma from patients taking amiloride for diuresis reduced pHi of leukemia and enhanced cytotoxic effects of kinase inhibitors and chemotherapy in vitro. NHE1-mediated intracellular alkalization played a key pathogenetic role in transmitting the proliferative signal from mutated-kinase and could be exploited for therapeutic intervention in AML.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells.\r\nDeletion of Cxcl12 leads to the accumulation of reactive oxygen species and DNA damage in LSCs, impairing their ability to perpetuate leukemia in transplantation experiments, a defect that can be attenuated by antioxidant therapy. Importantly, our data suggest that this phenomenon appears to be conserved in human patients. Hence, we have identified Prx1+ mesenchymal cells as an integral part of the complex niche-AML metabolic intertwining, pointing towards CXCL12/CXCR4 as a target to eradicate parenchymal LSCs in AML.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Association of Combined Lifestyle and Polygenetic Risk with Incidence of Venous Thromboembolism: A Large Population-Based Cohort Study.\r\nMoreover, of the participants with high genetic risk and unfavorable lifestyle, 2.90% developed VTE, versus 0.66% of the participants with low genetic risk and favorable lifestyle (HR: 4.09; 95% CI: 3.48-4.79). No significant interaction between genetic risk and lifestyle factors was observed ( for interaction=0.727). An unfavorable lifestyle was associated with a substantially higher risk of VTE, regardless of the genetic risk strata.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAutoimmune acquired factor XIII/13 deficiency after SARS-CoV-2 mRNA vaccination.\r\nnot required.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nContinuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders.\r\n pdFVIII and pdVWF administered by CI represent an effective and safe alternative to bolus injections in patients with severe HA or VWD undergoing surgery.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJoint effect of multiple prothrombotic genotypes and mean platelet volume on the risk of incident venous thromboembolism.\r\n The combination of high MPV and prothrombotic genotypes had an additive effect on VTE risk, suggesting there is no biological interaction between these risk factors in the pathogenesis of VTE.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nReviews&Editorials\r\nPlenty of the editorials are available as full text through the publisher website using the provided link\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#rqddydclyx .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#rqddydclyx .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rqddydclyx .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#rqddydclyx .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#rqddydclyx .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#rqddydclyx .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rqddydclyx .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#rqddydclyx .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#rqddydclyx .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#rqddydclyx .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#rqddydclyx .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#rqddydclyx .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#rqddydclyx .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#rqddydclyx .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#rqddydclyx .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#rqddydclyx .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#rqddydclyx .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#rqddydclyx .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#rqddydclyx .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#rqddydclyx .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#rqddydclyx .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#rqddydclyx .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#rqddydclyx .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#rqddydclyx .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rqddydclyx .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#rqddydclyx .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rqddydclyx .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#rqddydclyx .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#rqddydclyx .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#rqddydclyx .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#rqddydclyx .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#rqddydclyx .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#rqddydclyx .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#rqddydclyx .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#rqddydclyx .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood\r\n    A CAPTIVATE-ing new regimen for CLL.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nA cauldron of choices.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nActin powers the neutrophil traps.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnemia of inflammation is all the RAGE.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nQuenching the cytokine fire in the lungs.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRIG-Ing out BMSCs for hematopoietic recovery after transplantation.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTurning up the HEAT(R3) in Diamond-Blackfan anemia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions.\r\nThe goal of this review paper is to summarize and compare the various established risk stratification systems, go beyond the R-ISS and international myeloma working group risk stratifications to evaluate specific molecular and cytogenetic abnormalities and how they impact prognosis independently. In addition, we explore the wealth of new genomic information from recent whole genome/exome sequencing as well as gene expression data and review known clinical factors affecting outcome such as disease burden and early relapse as well as patient related factors such as race. Finally, we provide an outlook on developing a new high risk model system and how we might make sense of co-occurrences, oncogenic dependencies, and mutually exclusive mutations.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCA Cancer J Clin\r\n    Oncologic emergencies and urgencies: A comprehensive review. \r\nEmergent and urgent complications associated with targeted therapeutics, including small molecules, naked and drug-conjugated monoclonal antibodies, as well as immune checkpoint inhibitors and chimeric antigen receptor T-cells, are summarized. Finally, strategies for facilitating same-day direct admission to hospice from the ED are discussed. This article not only can serve as a point-of-care reference for the ED physician but also can assist outpatient oncologists as well as inpatient hospitalists in coordinating care around the ED visit.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    Treatment of drug-induced immune thrombocytopenias.\r\nWhile DITP is commonly associated with an increased risk of bleeding, HIT and VITT have a high mortality rate due to the high incidence of thromboembolic complications. A structured approach to drug-associated thrombocytopenia/thrombosis can lead to successful treatment and a lower mortality rate. In addition to describing the treatment of DITP, HIT, VITT, and vaccine-associated immune thrombocytopenia, this review also provides the pathophysiological and clinical information necessary for correct patient management.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTreatment of inherited thrombocytopenias.\r\nOn the other hand, it has become evident that some of the mutations responsible for platelet deficiency predispose the patient to serious, potentially lifethreatening diseases. Today's vision of IT is, therefore, very different from that of the past and the therapeutic approach must take these changes into account while also making use of the new therapies that have become available in the meantime. This review, the first devoted entirely to IT therapy, discusses how to prevent bleeding in those patients who are exposed to this risk, how to treat it if it occurs, and how to manage the serious illnesses to which patients with IT may be predisposed.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    Sickle cell disease: a year in review. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. \r\nBecause of the large inter-individual variations in MTX/6-MP bioavailability and metabolism, dose adjustments are traditionally guided by the degree of myelosuppression, but this does not accurately reflect treatment intensity. DNA-TG is a common downstream metabolite of MTX/6-MP combination chemotherapy, and a higher level of DNA-TG has been associated with a lower relapse hazard, leading to the development of the Thiopurine Enhanced ALL Maintenance (TEAM) strategy-the addition of low-dose (2.5-12.5mg/m2/day) 6-thioguanine to the 6-MP/MTX backbone-that is currently being tested in a randomized ALLTogether1 trial (EudraCT: 2018-001795-38). Mutations in the thiopurine and MTX metabolism pathways, and in the mismatch repair genes have been identified in early ALL relapses, providing valuable insights to assist the development of strategies to detect imminent relapse, to facilitate relapse salvage therapy, and even to bring about changes in frontline ALL therapy to mitigate this relapse risk.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nLetters&Replies\r\nLetters to the editors and authorsâ€™ replies\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#dynwflicjg .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#dynwflicjg .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#dynwflicjg .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#dynwflicjg .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#dynwflicjg .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#dynwflicjg .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#dynwflicjg .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#dynwflicjg .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#dynwflicjg .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#dynwflicjg .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#dynwflicjg .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#dynwflicjg .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#dynwflicjg .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#dynwflicjg .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#dynwflicjg .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#dynwflicjg .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#dynwflicjg .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#dynwflicjg .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#dynwflicjg .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#dynwflicjg .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#dynwflicjg .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#dynwflicjg .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#dynwflicjg .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#dynwflicjg .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#dynwflicjg .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#dynwflicjg .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#dynwflicjg .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#dynwflicjg .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#dynwflicjg .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#dynwflicjg .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#dynwflicjg .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#dynwflicjg .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#dynwflicjg .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#dynwflicjg .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#dynwflicjg .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Incident users of tyrosine kinase inhibitors in chronic myeloid leukemia patients: analysis of anticancer treatment trajectories - A French population-based study using the French national health data system.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIntrathecal Prophylaxis with 12 Versus 8 Administrations Reduces the Incidence of Central Nervous System Relapse in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnn Oncol\r\n    Does the result of a small-scale phase II study of nivolumab for cancer of unknown primary justify regulatory approval?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Potential role of STAG1 mutations in genetic predisposition to childhood hematological malignancies. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nUnique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    Prehospital blood transfusion for haemorrhagic shock - Authors' reply. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPrehospital blood transfusion for haemorrhagic shock. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPrehospital blood transfusion for haemorrhagic shock. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPrehospital blood transfusion for haemorrhagic shock. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nOthers\r\nall remaining publications eg case reports, images of the month, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#tcxbrlzknk .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#tcxbrlzknk .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#tcxbrlzknk .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#tcxbrlzknk .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#tcxbrlzknk .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#tcxbrlzknk .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#tcxbrlzknk .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#tcxbrlzknk .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#tcxbrlzknk .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#tcxbrlzknk .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#tcxbrlzknk .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#tcxbrlzknk .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#tcxbrlzknk .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#tcxbrlzknk .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#tcxbrlzknk .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#tcxbrlzknk .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#tcxbrlzknk .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#tcxbrlzknk .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#tcxbrlzknk .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#tcxbrlzknk .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#tcxbrlzknk .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#tcxbrlzknk .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#tcxbrlzknk .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#tcxbrlzknk .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#tcxbrlzknk .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#tcxbrlzknk .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#tcxbrlzknk .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#tcxbrlzknk .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#tcxbrlzknk .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#tcxbrlzknk .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#tcxbrlzknk .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#tcxbrlzknk .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#tcxbrlzknk .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#tcxbrlzknk .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#tcxbrlzknk .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Circulating Rhabdoid Tumor Cells in the Peripheral Blood of a Neonate.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Hemophagocytic lymphohistiocytosis with multiple possible etiologies including rare primary bone marrow lymphoma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHenden AS, Koyama M, Robb RJ, etÂ al. IFN- therapy prevents severe gastrointestinal graft-versus-host disease. Blood. 2021;138(8):722-737.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSclerosing extramedullary hematopoietic tumor in chronic myeloproliferative neoplasms.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nYu Z, Yang W, He X, etÂ al. Endothelial cell-derived angiopoietin-like protein 2 supports hematopoietic stem cell activities in bone marrow niches. Blood. 2022;139(10):1529-1540.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Direct Oral Xa Inhibitors for the Treatment of Venous Thromboembolism After Bariatric Surgery.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nVirtual frailty assessment for older adults with hematologic malignancies.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    Images from the Haematologica Atlas of Hematologic Cytology: abnormalities of platelet shape.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIntroduction to a review series on the treatment of thrombocytopenic disorders: something old, something new.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPost-transplant cyclophosphamide: overcoming the HLA barrier to hematopoietic stem cell transplants.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    A curious case of a neutrophilic horn. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBedside art is good medicine. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFuture role of topical pimecrolimus in early stage mycosis fungoides? \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Germline PTPN13 mutations in patients with bone marrow failure and acute lymphoblastic leukemia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nREDD1 is a gatekeeper of murine hematopoietic stem cell functions during stress responses.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n// add bootstrap table styles to pandoc tables\r\nfunction bootstrapStylePandocTables() {\r\n  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');\r\n}\r\n$(document).ready(function () {\r\n  bootstrapStylePandocTables();\r\n});\r\n\r\n\r\n\r\n$(document).ready(function () {\r\n  window.buildTabsets(\"TOC\");\r\n});\r\n\r\n$(document).ready(function () {\r\n  $('.tabset-dropdown > .nav-tabs > li').click(function () {\r\n    $(this).parent().toggleClass('nav-tabs-open');\r\n  });\r\n});\r\n\r\n  (function () {\r\n    var script = document.createElement(\"script\");\r\n    script.type = \"text/javascript\";\r\n    script.src  = \"https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML\";\r\n    document.getElementsByTagName(\"head\")[0].appendChild(script);\r\n  })();\r\n\r\n\r\n\r\n\r\n\r\n",
    "preview": {},
    "last_modified": "2022-06-03T17:30:30-04:00",
    "input_file": {}
  }
]
